[Congressional Record Volume 164, Number 103 (Wednesday, June 20, 2018)]
[House]
[Pages H5304-H5325]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]
COORDINATED RESPONSE THROUGH INTERAGENCY STRATEGY AND INFORMATION
SHARING ACT
Mr. MITCHELL. Mr. Speaker, I move to suspend the rules and pass the
bill (H.R. 5925) to codify provisions relating to the Office of
National Drug Control, and for other purposes, as amended.
The Clerk read the title of the bill.
The text of the bill is as follows:
H.R. 5925
Be it enacted by the Senate and House of Representatives of
the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Coordinated Response through
Interagency Strategy and Information Sharing Act'' or the
``CRISIS Act''.
SEC. 2. OFFICE OF NATIONAL DRUG CONTROL.
(a) Redesignation.--The Office of National Drug Control
Policy shall be known as the ``Office of National Drug
Control''.
(b) References.--Any reference in any other Federal law,
Executive order, rule, regulation, or delegation of
authority, or any document of or relating to the Office of
National Drug Control Policy is deemed to refer to the Office
of National Drug Control.
(c) Codification.--Subtitle I of title 31, United States
Code, is amended by adding at the end the following new
chapter:
``CHAPTER 10--OFFICE OF NATIONAL DRUG CONTROL
``subchapter i--office
``1001. Definitions.
``1002. Office of National Drug Control.
``1003. Administration of the Office.
``1004. National drug control program budget.
``1005. National drug control strategy.
``1006. Development of an annual national drug control assessment.
``1007. Monitoring and evaluation of national drug control program.
``1008. Coordination and oversight of the national drug control
program.
[[Page H5305]]
``1009. Emerging threats task force, plan, campaign.
``1010. National and international coordination.
``1011. Interdiction.
``1012. Treatment coordinator.
``1013. Critical information coordination.
``1014. Authorization of appropriations.
``subchapter ii--drug-free communities support program
``1021. Establishment of drug-free communities support program.
``1022. Program authorization.
``1023. Information collection and dissemination with respect to grant
recipients.
``1024. Technical assistance and training.
``1025. Supplemental grants for coalition mentoring activities.
``1026. Authorization for National Community Antidrug Coalition
Institute.
``1027. Definitions.
``1028. Drug-free communities reauthorization.
``SUBCHAPTER I--OFFICE
``Sec. 1001. Definitions
``In this chapter:
``(1) Agency.--The term `agency' has the meaning given the
term `executive agency' in section 102.
``(2) Appropriate congressional committees.--
``(A) In general.--The term `appropriate congressional
committees' means--
``(i) the Committee on the Judiciary, the Committee on
Appropriations, the Committee on Health, Education, Labor,
and Pensions, and the Caucus on International Narcotics
Control of the Senate; and
``(ii) the Committee on Oversight and Government Reform,
the Committee on the Judiciary, the Committee on Energy and
Commerce, and the Committee on Appropriations of the House of
Representatives.
``(B) Submission to congress.--Any submission to Congress
shall mean submission to the appropriate congressional
committees.
``(3) Demand reduction.--The term `demand reduction' means
any activity conducted by a National Drug Control Program
Agency, other than an enforcement activity, that is intended
to reduce or prevent the use of drugs or support or provide
treatment and recovery efforts, including--
``(A) education about the dangers of illicit drug use;
``(B) services, programs, or strategies to prevent
substance use disorder, including evidence-based education
campaigns, community-based prevention programs, collection
and disposal of unused prescription drugs, and services to
at-risk populations to prevent or delay initial use of an
illicit drug;
``(C) substance use disorder treatment;
``(D) illicit drug use research;
``(E) drug-free workplace programs;
``(F) drug testing, including the testing of employees;
``(G) interventions for illicit drug use and dependence;
``(H) expanding availability of access to health care
services for the treatment of substance use disorders;
``(I) international drug control coordination and
cooperation with respect to activities described in this
paragraph;
``(J) pre- and post-arrest criminal justice interventions
such as diversion programs, drug courts, and the provision of
evidence-based treatment to individuals with substance use
disorders who are arrested or under some form of criminal
justice supervision, including medication assisted treatment;
``(K) other coordinated and joint initiatives among
Federal, State, local, and Tribal agencies to promote
comprehensive drug control strategies designed to reduce the
demand for, and the availability of, illegal drugs;
``(L) international illicit drug use education, prevention,
treatment, recovery, research, rehabilitation activities, and
interventions for illicit drug use and dependence; and
``(M) research related to any of the activities described
in this paragraph.
``(4) Director.--The term `Director' means the Director of
the Office of National Drug Control.
``(5) Drug.--The term `drug' has the meaning given the term
`controlled substance' in section 102(6) of the Controlled
Substances Act (21 U.S.C. 802(6)).
``(6) Drug control.--The term `drug control' means any
activity conducted by a National Drug Control Program Agency
involving supply reduction or demand reduction.
``(7) Emerging drug threat.--The term `emerging drug
threat' means the occurrence of a new and growing trend in
the use of an illicit drug or class of drugs, including rapid
expansion in the supply of or demand for such drug.
``(8) Illicit drug use; illicit drugs; illegal drugs.--The
terms `illicit drug use', `illicit drugs', and `illegal
drugs' include the illegal or illicit use of prescription
drugs.
``(9) Law enforcement.--The term `law enforcement' or `drug
law enforcement' means all efforts by a Federal, State,
local, or Tribal government agency to enforce the drug laws
of the United States or any State, including investigation,
arrest, prosecution, and incarceration or other punishments
or penalties.
``(10) National drug control program.--The term `National
Drug Control Program' means programs, policies, and
activities undertaken by National Drug Control Program
Agencies pursuant to the responsibilities of such agencies
under the National Drug Control Strategy, including any
activities involving supply reduction, demand reduction, or
State, local, and Tribal affairs.
``(11) National drug control program agency.--The term
`National Drug Control Program Agency' means any agency (or
bureau, office, independent agency, board, division,
commission, subdivision, unit, or other component thereof)
that is responsible for implementing any aspect of the
National Drug Control Strategy, including any agency that
receives Federal funds to implement any aspect of the
National Drug Control Strategy, but does not include any
agency that receives funds for drug control activity solely
under the National Intelligence Program or the Military
Intelligence Program.
``(12) National drug control strategy; strategy.--The term
`National Drug Control Strategy' or `Strategy' means the
strategy developed and submitted to Congress under section
1005.
``(13) Nonprofit organization.--The term `nonprofit
organization' means an organization that is described in
section 501(c)(3) of the Internal Revenue Code of 1986 and
exempt from tax under section 501(a) of such Code.
``(14) Office.--The term `Office' means the Office of
National Drug Control.
``(15) State, local, and tribal affairs.--The term `State,
local, and Tribal affairs' means domestic activities
conducted by a National Drug Control Program Agency that are
intended to reduce the availability and use of illegal drugs,
including--
``(A) coordination and enhancement of Federal, State,
local, and Tribal law enforcement drug control efforts;
``(B) coordination and enhancement of efforts among
National Drug Control Program Agencies and State, local, and
Tribal demand reduction and supply reduction agencies;
``(C) coordination and enhancement of Federal, State,
local, and Tribal law enforcement initiatives to gather,
analyze, and disseminate information and law enforcement
intelligence relating to drug control among domestic law
enforcement agencies; and
``(D) other coordinated and joint initiatives among
Federal, State, local, and Tribal agencies to promote
comprehensive drug control strategies designed to reduce the
demand for, and the availability of, illegal drugs.
``(16) Substance use disorder treatment.--The term
`substance use disorder treatment' means an evidence-based,
professionally directed, deliberate, and planned regimen
including evaluation, observation, medical monitoring, and
rehabilitative services and interventions such as
pharmacotherapy, behavioral therapy, and individual and group
counseling, on an inpatient or outpatient basis, to help
patients with substance use disorder reach recovery.
``(17) Supply reduction.--The term `supply reduction' means
any activity or program conducted by a National Drug Control
Program Agency that is intended to reduce the availability or
use of illegal drugs in the United States or abroad,
including--
``(A) law enforcement outside the United States;
``(B) domestic law enforcement;
``(C) source country programs, including economic
development programs primarily intended to reduce the
production or trafficking of illicit drugs;
``(D) activities to control international trafficking in,
and availability of, illegal drugs, including--
``(i) accurate assessment and monitoring of international
drug production and interdiction programs and policies; and
``(ii) coordination and promotion of compliance with
international treaties relating to the production,
transportation, or interdiction of illegal drugs;
``(E) activities to conduct and promote international law
enforcement programs and policies to reduce the supply of
drugs;
``(F) activities to facilitate and enhance the sharing of
domestic and foreign intelligence information among National
Drug Control Program Agencies, relating to the production and
trafficking of drugs in the United States and in foreign
countries;
``(G) activities to prevent the diversion of drugs for
their illicit use; and
``(H) research related to any of the activities described
in this paragraph.
``Sec. 1002. Office of National Drug Control
``(a) Establishment of Office.--There is established in the
Executive Office of the President an Office of National Drug
Control, which shall--
``(1) lead the national drug control effort, including
coordinating with Nation Drug Control Program Agencies;
``(2) coordinate and oversee the implementation of the
national drug control policy, including the National Drug
Control Strategy;
``(3) assess and certify the adequacy of National Drug
Control Programs and the budget for those programs;
``(4) monitor and evaluate the effectiveness of national
drug control policy efforts, including the National Drug
Control Program Agencies' programs, by developing and
applying specific goals and performance measurements and
tracking program-level spending;
``(5) identify and respond to emerging drug threats related
to illicit drug use;
[[Page H5306]]
``(6) administer and evaluate grant programs in furtherance
of the National Drug Control Strategy; and
``(7) facilitate broad-scale information sharing and data
standardization among Federal, State, and local entities to
support the national drug control efforts.
``(b) Director of National Drug Control and Deputy
Director.--
``(1) Director.--
``(A) In general.--There shall be at the head of the Office
a Director who shall hold the same rank and status as the
head of an executive department listed in section 101 of
title 5.
``(B) Appointment.--The Director shall be appointed by the
President, by and with the advice and consent of the Senate,
and shall serve at the pleasure of the President.
``(2) Deputy director.--
``(A) In general.--There shall be a Deputy Director who
shall report directly to the Director, be appointed by the
President, and serve at the pleasure of the President.
``(B) Responsibilities.--The Deputy Director shall--
``(i) carry out the responsibilities delegated by the
Director; and
``(ii) be responsible for effectively coordinating with the
each Coordinator established under this chapter.
``(c) Responsibilities.--
``(1) Policies, goals, objectives, and priorities.--The
Director shall assist the President in directing national
drug control efforts, including establishing policies, goals,
objectives, and priorities for the National Drug Control
Program that are based on evidence-based research.
``(2) Consultation.--To formulate the National Drug Control
policies, goals, objectives, and priorities, the Director--
``(A) shall consult with--
``(i) State and local governments;
``(ii) National Drug Control Program Agencies;
``(iii) each committee, working group, council, or other
entity established under this chapter, as appropriate;
``(iv) the public;
``(v) appropriate congressional committees; and
``(vi) any other person in the discretion of the Director;
and
``(B) may--
``(i) establish advisory councils;
``(ii) acquire data from agencies; and
``(iii) request data from any other entity.
``Sec. 1003. Administration of the Office
``(a) Employment.--
``(1) Authority of the director.--The Director may select,
appoint, employ, and fix compensation of such officers and
employees of the Office as may be necessary to carry out the
functions of the Office under this chapter.
``(2) Prohibitions.--
``(A) Generally.--No person shall serve as Director or
Deputy Director while serving in any other position in the
Federal Government.
``(B) Prohibition on political campaigning.--Any officer or
employee of the Office who is appointed to that position by
the President, by and with the advice and consent of the
Senate, may not participate in Federal election campaign
activities, except that such officer or employee is not
prohibited by this subparagraph from making contributions to
individual candidates.
``(b) Prohibition on the Use of Funds for Political
Campaigns or Ballot Initiatives.--No funds authorized under
this chapter may be obligated for the purpose of influencing
any Federal, State, or local election or ballot initiative.
``(c) Personnel Detailed to Office.--
``(1) Evaluations.--Notwithstanding any provision of
chapter 43 of title 5, the Director shall perform the
evaluation of the performance of any employee detailed to the
Office for purposes of the applicable performance appraisal
system established under such chapter for any rating period,
or part thereof, that such employee is detailed to the
Office.
``(2) Compensation.--
``(A) Bonus payments.--Subject to the availability of
appropriations, the Director may provide periodic bonus
payments to any employee detailed to the Office.
``(B) Restrictions.--An amount paid under this paragraph to
an employee for any period--
``(i) shall not be greater than 20 percent of the basic pay
paid or payable to such employee for such period; and
``(ii) shall be in addition to the basic pay of such
employee.
``(C) Aggregate amount.--The aggregate amount paid during
any fiscal year to an employee detailed to the Office as
basic pay, awards, bonuses, and other compensation shall not
exceed the annual rate payable at the end of such fiscal year
for positions at level III of the Executive Schedule.
``(d) Congressional Access to Information.--The location of
the Office in the Executive Office of the President shall not
be construed as affecting access by Congress, or any
committee of the House of Representatives or the Senate, to
any--
``(1) information, document, or study in the possession of,
or conducted by or at the direction of the Director; or
``(2) personnel of the Office.
``(e) Other Authorities of the Director.--In carrying out
this chapter, the Director may--
``(1) use for administrative purposes, on a reimbursable
basis, the available services, equipment, personnel, and
facilities of Federal, State, and local agencies;
``(2) procure the services of experts and consultants in
accordance with section 3109 of title 5 relating to
appointments in the Federal Service, at rates of compensation
for individuals not to exceed the daily equivalent of the
rate of pay payable under level IV of the Executive Schedule
under section 5311 of such title; and
``(3) use the mails in the same manner as any other agency.
``(f) General Services Administration.--The Administrator
of General Services shall provide to the Director, on a
reimbursable basis, such administrative support services as
the Director may request.
``Sec. 1004. National drug control program budget
``(a) Budget Recommendations.--Not later than July 1 of
each year, the Director shall provide to the head of each
National Drug Control Program Agency budget recommendations,
including requests for specific initiatives that are
consistent with the priorities of the President under the
National Drug Control Strategy, which shall--
``(1) apply to the budget for the next fiscal year
scheduled for formulation under chapter 11, and each of the 4
subsequent fiscal years; and
``(2) address funding priorities developed in the National
Drug Control Strategy.
``(b) Responsibilities of National Drug Control Program
Agencies.--
``(1) In general.--For each fiscal year, the head of each
National Drug Control Program Agency shall transmit to the
Director a copy of the proposed drug control budget request
of such agency at the same time as that budget request is
submitted to their superiors (and before submission to the
Office of Management and Budget) in the preparation of the
budget of the President submitted to Congress under section
1105(a).
``(2) Submission of drug control budget requests.--The head
of each National Drug Control Program Agency shall ensure
timely development and submission to the Director of each
proposed drug control budget request transmitted pursuant to
this subsection, in such format as may be designated by the
Director with the concurrence of the Director of the Office
of Management and Budget.
``(3) Content of drug control budget requests.--A drug
control budget request submitted by the head of a National
Drug Control Program Agency under this subsection shall
include all requests for funds for any drug control activity
undertaken by such agency, including demand reduction, supply
reduction, and State, local, and Tribal affairs, including
any drug law enforcement activities. If an activity has both
drug control and nondrug control purposes or applications,
such agency shall estimate by a documented calculation the
total funds requested for that activity that would be used
for drug control, and shall set forth in its request the
basis and method for making the estimate.
``(c) Review and Certification of Budget Requests and
Budget Submissions of National Drug Control Program
Agencies.--
``(1) In general.--The Director shall review each drug
control budget request submitted to the Director under
subsection (b).
``(2) Review of budget requests.--
``(A) Inadequate requests.--If the Director concludes that
a budget request submitted under subsection (b) is
inadequate, in whole or in part, to implement the objectives
of the National Drug Control Strategy with respect to the
agency or program at issue for the year for which the request
is submitted, the Director shall submit to the head of the
applicable National Drug Control Program Agency a written
description identifying the funding levels and specific
initiatives that would, in the determination of the Director,
make the request adequate to implement those objectives.
``(B) Adequate requests.--If the Director concludes that a
budget request submitted under subsection (b) is adequate to
implement the objectives of the National Drug Control
Strategy with respect to the agency or program at issue for
the year for which the request is submitted, the Director
shall submit to the head of the applicable National Drug
Control Program Agency a written statement confirming the
adequacy of the request.
``(C) Record.--The Director shall maintain a record of each
description submitted under subparagraph (A) and each
statement submitted under subparagraph (B).
``(3) Specific requests.--The Director shall not confirm
the adequacy of any budget request that requests a level of
funding that will not enable achievement of the goals of the
National Drug Control Strategy, including--
``(A) requests funding for Federal law enforcement
activities that do not adequately compensate for transfers of
drug enforcement resources and personnel to law enforcement
and investigation activities;
``(B) requests funding for law enforcement activities on
the borders of the United States that do not adequately
direct resources to drug interdiction and enforcement;
``(C) requests funding for substance use disorder treatment
activities that do not provide adequate results and
accountability measures;
``(D) requests funding for substance use disorder treatment
activities that do not adequately support and enhance Federal
substance use disorder programs and capacity; and
[[Page H5307]]
``(E) requests funding for the operations and management of
the Department of Homeland Security that does not include a
specific request for funds for the Office of Counternarcotics
Enforcement to carry out its responsibilities under section
878 of the Homeland Security Act of 2002 (6 U.S.C. 458).
``(4) Agency response.--
``(A) In general.--The head of a National Drug Control
Program Agency that receives a description under paragraph
(2)(A) shall include the funding levels and initiatives
described by the Director in the budget submission for that
agency to the Office of Management and Budget.
``(B) Impact statement.--The head of a National Drug
Control Program Agency that has altered its budget submission
under this paragraph shall include as an appendix to the
budget submission for that agency to the Office of Management
and Budget an impact statement that summarizes--
``(i) the changes made to the budget under this paragraph;
and
``(ii) the impact of those changes on the ability of that
agency to perform its other responsibilities, including any
impact on specific missions or programs of the agency.
``(C) Congressional notification.--The head of a National
Drug Control Program Agency shall submit a copy of any impact
statement under subparagraph (B) to the Senate, the House of
Representatives, and the appropriate congressional
committees, at the time the budget for that agency is
submitted to Congress under section 1105(a).
``(5) Certification of budget submissions.--
``(A) In general.--At the time the head of a National Drug
Control Program Agency submits its budget request to the
Office of Management and Budget, the head of the National
Drug Control Program Agency shall submit a copy of the budget
request to the Director.
``(B) Review and certification of submissions.--The
Director shall review each budget submission submitted under
subparagraph (A) and submit to the appropriate congressional
committees one of the following:
``(i) A written certification of the budget submission for
the agency indicating such request fully funds the National
Drug Control Programs as necessary to achieve the goals of
the National Drug Control Strategy, including a written
statement explaining the basis for the determination that the
budget submission provides sufficient resources for the
agency to achieve the goals of the Strategy.
``(ii) A written certification of the budget submission for
the agency indicating such request partially funds the
National Drug Control Programs as necessary to achieve the
goals of the Strategy, including a written statement
explaining the basis for the determination to certify the
budget submission and identifying the level of funding
sufficient to achieve the goals of the Strategy.
``(iii) A written decertification of the budget submission
for the agency indicating the Director is unable to determine
whether such budget submission for the agency fully funds or
partially funds the National Drug Control Programs as
necessary to achieve the goals of the National Drug Control
Strategy, including a written statement identifying the
additional information necessary for the Director to make a
determination on such budget submission and the level of
funding sufficient to achieve the goals of the Strategy.
``(iv) A written decertification of the budget submission
for the agency indicating that such budget is insufficient to
fund the National Drug Control Programs as necessary to
achieve the goals of the Strategy, including a written
statement explaining the basis for the determination that the
budget is insufficient and identifying the level of funding
sufficient to achieve the goals of the Strategy.
``(d) National Drug Control Program Budget Proposal.--For
each fiscal year, following the transmission of proposed drug
control budget requests to the Director under subsection (b),
the Director shall, in consultation with the head of each
National Drug Control Program Agency and the head of each
major national organization that represents law enforcement
officers, agencies, or associations--
``(1) develop a consolidated National Drug Control Program
budget proposal designed to implement the National Drug
Control Strategy and to inform Congress and the public about
the total amount proposed to be spent on all supply
reduction, demand reduction, State, local, and Tribal
affairs, including any drug law enforcement, and other drug
control activities by the Federal Government, which shall
conform to the content requirements set forth in subsection
(b)(3) and include--
``(A) for each National Drug Control Program Agency, a list
of whether the funding level is full, partial, or
insufficient to achieve the goals of the National Drug
Control Strategy or whether the Director is unable to make
such determination;
``(B) a statement describing the extent to which any budget
of a National Drug Control Program Agency with less than full
funding hinders progress on achieving the goals of the
National Drug Control Strategy; and
``(C) alternative funding structures that could improve
progress on achieving the goals of the National Drug Control
Strategy; and
``(2) submit the consolidated budget proposal to the
President and Congress.
``(e) Budget Estimate or Request Submission to Congress.--
Whenever the Director submits any budget estimate or request
to the President or the Office of Management and Budget, the
Director shall concurrently transmit to the appropriate
congressional committees a detailed statement of the
budgetary needs of the Office to execute its mission based on
the good-faith assessment of the Director.
``(f) Reprogramming and Transfer Requests.--
``(1) In general.--No National Drug Control Program Agency
shall submit to Congress a reprogramming or transfer request
with respect to any amount of appropriated funds in an amount
exceeding $1,000,000 that is included in the National Drug
Control Program budget unless the request has been approved
by the Director. If the Director has not responded to a
request for reprogramming subject to this paragraph within 30
days after receiving notice of the request having been made,
the request shall be deemed approved by the Director under
this paragraph and forwarded to Congress.
``(2) Appeal.--The head of any National Drug Control
Program Agency may appeal to the President any disapproval by
the Director of a reprogramming or transfer request under
this subsection.
``Sec. 1005. National drug control strategy
``(a) In General.--
``(1) Statement of drug policy priorities.--The Director
shall release a statement of drug control policy priorities
in the calendar year of a Presidential inauguration following
the inauguration but not later than April 1.
``(2) National drug control strategy submitted by the
president.--Not later than the first Monday in February
following the year in which the term of the President
commences, the President shall submit to Congress a National
Drug Control Strategy.
``(b) Development of the National Drug Control Strategy.--
``(1) Promulgation.--The Director shall promulgate the
National Drug Control Strategy, which shall set forth a
comprehensive plan to reduce illicit drug use and the
consequences of such illicit drug use in the United States by
limiting the availability of and reducing the demand for
illegal drugs and promoting prevention, early intervention,
treatment, and recovery support for individuals with
substance use disorders.
``(2) State and local commitment.--The Director shall seek
the support and commitment of State, local, and Tribal
officials in the formulation and implementation of the
National Drug Control Strategy.
``(3) Strategy based on evidence.--The Director shall
ensure the National Drug Control Strategy is based on the
best available medical and scientific evidence regarding the
policies that are most effective in reducing the demand for
and supply of illegal drugs.
``(4) Process for development and submission of national
drug control strategy.--In developing and effectively
implementing the National Drug Control Strategy, the
Director--
``(A) shall consult with--
``(i) the heads of the National Drug Control Program
Agencies;
``(ii) each Coordinator established under this chapter;
``(iii) the Interdiction Committee, the Treatment
Committee, and the Emerging Threats Task Force;
``(iv) the appropriate congressional committees and any
other committee of jurisdiction;
``(v) State, local, and Tribal officials;
``(vi) private citizens and organizations, including
community and faith-based organizations, with experience and
expertise in demand reduction;
``(vii) private citizens and organizations with experience
and expertise in supply reduction; and
``(viii) appropriate representatives of foreign
governments; and
``(B) in satisfying the requirements of subparagraph (A),
shall ensure, to the maximum extent possible, that State,
local, and Tribal officials and relevant private
organizations commit to support and take steps to achieve the
goals and objectives of the National Drug Control Strategy.
``(c) Contents of the National Drug Control Strategy.--
``(1) In general.--The National Drug Control Strategy
submitted under subsection (a)(2) shall include the
following:
``(A) A description of the current prevalence of illicit
drug use in the United States, including both the
availability of illicit drugs and the prevalence of substance
use disorders, which shall include the following:
``(i) Such description for the previous three years for any
drug identified as an emerging threat under section 1009 and
any other illicit drug identified by the Director as having a
significant impact on the prevalence of illicit drug use.
``(ii) A summary of the data and trends presented in the
Drug Control Data Dashboard required under section 1013.
``(B) A mission statement detailing the major functions of
the National Drug Control Program.
``(C) A list of comprehensive, research-based, long-range,
quantifiable goals for reducing illicit drug use, including--
``(i) the percentage of the total flow of illicit drugs to
be interdicted during the time period covered by the
Strategy; and
``(ii) the number of individuals to receive substance use
disorder treatment.
[[Page H5308]]
``(D) A description of how each goal established under
subparagraph (C) will be achieved, including for each goal--
``(i) a list of each relevant National Drug Control Program
Agency and each such agency's related programs, activities,
and available assets and the role of each such program,
activity, and asset in achieving such goal;
``(ii) a list of relevant stakeholders and each such
stakeholder's role in achieving such goal;
``(iii) an estimate of Federal funding and other resources
needed to achieve such goal;
``(iv) a list of each existing or new coordinating
mechanism needed to achieve such goal; and
``(v) a description of the Office's role in facilitating
the achievement of such goal.
``(E) For each year covered by the Strategy, a performance
evaluation plan for each goal established under subparagraph
(C) for each National Drug Control Program Agency,
including--
``(i) specific performance measures for each National Drug
Control Program Agency and each such agency's related
programs and activities;
``(ii) annual and, to the extent practicable, quarterly
objectives and targets for each performance measure; and
``(iii) an estimate of Federal funding and other resources
needed to achieve each performance objective and target.
``(F) A list identifying existing data sources or a
description of data collection needed to evaluate
performance, including a description of how the Director will
obtain such data.
``(G) A list of any anticipated challenges to achieving the
National Drug Control Strategy goals and planned actions to
address such challenges.
``(H) A description of how each goal established under
subparagraph (C) was determined, including--
``(i) a description of each required consultation and a
description of how such consultation was incorporated;
``(ii) data, research, or other information used to inform
the determination to establish the goal; and
``(iii) for any goal established under subparagraph (C)(i),
a statement of whether the goal will be adequate to disrupt
drug trafficking organizations that supply the majority of
foreign-sourced illicit drugs trafficked into the United
States.
``(I) A 5-year projection for program and budget
priorities.
``(J) A review of international, State, local, and private
sector drug control activities to ensure that the United
States pursues coordinated and effective drug control at all
levels of government.
``(K) Such statistical data and information as the Director
considers appropriate to demonstrate and assess trends
relating to illicit drug use, the effects and consequences of
illicit drug use (including the effects on children), supply
reduction, demand reduction, drug-related law enforcement,
and the implementation of the National Drug Control Strategy.
``(2) Additional strategies.--
``(A) In general.--The Director shall include in the
National Drug Control Strategy the additional strategies
described under this paragraph and shall comply with the
following:
``(i) Provide a copy of the additional strategies to the
appropriate congressional committees and to the Committee on
Armed Services and the Committee on Homeland Security of the
House of Representatives, and the Committee on Homeland
Security and Governmental Affairs and the Committee on Armed
Services of the Senate.
``(ii) Issue the additional strategies in consultation with
the head of each relevant National Drug Control Program
Agency, any relevant official of a State, local, or Tribal
government, and the government of other relevant countries.
``(iii) Not change any existing agency authority or
construe any strategy described under this paragraph to amend
or modify any law governing interagency relationship but may
include recommendations about changes to such authority or
law.
``(iv) Present separately from the rest of any strategy
described under this paragraph any information classified
under criteria established by an Executive order, or whose
public disclosure, as determined by the Director or the head
of any relevant National Drug Control Program Agency, would
be detrimental to the law enforcement or national security
activities of any Federal, State, local, or Tribal agency.
``(B) Requirement for southwest border counternarcotics.--
``(i) Purposes.--The Southwest Border Counternarcotics
Strategy shall--
``(I) set forth the Government's strategy for preventing
the illegal trafficking of drugs across the international
border between the United States and Mexico, including
through ports of entry and between ports of entry on that
border;
``(II) state the specific roles and responsibilities of the
relevant National Drug Control Program Agencies for
implementing that strategy; and
``(III) identify the specific resources required to enable
the relevant National Drug Control Program Agencies to
implement that strategy.
``(ii) Specific content related to drug tunnels between the
united states and mexico.--The Southwest Border
Counternarcotics Strategy shall include--
``(I) a strategy to end the construction and use of tunnels
and subterranean passages that cross the international border
between the United States and Mexico for the purpose of
illegal trafficking of drugs across such border; and
``(II) recommendations for criminal penalties for persons
who construct or use such a tunnel or subterranean passage
for such a purpose.
``(C) Requirement for northern border counternarcotics
strategy.--
``(i) Purposes.--The Northern Border Counternarcotics
Strategy shall--
``(I) set forth the strategy of the Federal Government for
preventing the illegal trafficking of drugs across the
international border between the United States and Canada,
including through ports of entry and between ports of entry
on the border;
``(II) state the specific roles and responsibilities of
each relevant National Drug Control Program Agency for
implementing the strategy;
``(III) identify the specific resources required to enable
the relevant National Drug Control Program Agencies to
implement the strategy;
``(IV) be designed to promote, and not hinder, legitimate
trade and travel; and
``(V) reflect the unique nature of small communities along
the international border between the United States and
Canada, ongoing cooperation and coordination with Canadian
law, enforcement authorities, and variations in the volumes
of vehicles and pedestrians crossing through ports of entry
along the international border between the United States and
Canada.
``(ii) Specific content related to cross-border indian
reservations.--The Northern Border Counternarcotics Strategy
shall include--
``(I) a strategy to end the illegal trafficking of drugs to
or through Indian reservations on or near the international
border between the United States and Canada; and
``(II) recommendations for additional assistance, if any,
needed by Tribal law enforcement agencies relating to the
strategy, including an evaluation of Federal technical and
financial assistance, infrastructure capacity building, and
interoperability deficiencies.
``(3) Classified information.--Any contents of the National
Drug Control Strategy that involve information properly
classified under criteria established by an Executive order
shall be presented to Congress separately from the rest of
the National Drug Control Strategy.
``(4) Selection of data and information.--In selecting data
and information for inclusion in the Strategy, the Director
shall ensure--
``(A) the inclusion of data and information that will
permit analysis of current trends against previously compiled
data and information where the Director believes such
analysis enhances long-term assessment of the National Drug
Control Strategy; and
``(B) the inclusion of data and information to permit a
standardized and uniform assessment of the effectiveness of
drug treatment programs in the United States.
``(d) Annual Performance Supplement.--Not later than the
first Monday in February of each year following the year in
which the National Drug Control Strategy is submitted
pursuant to subsection (a)(2), the Director shall submit to
the appropriate congressional committees a supplement to the
Strategy that shall include--
``(1) annual and, to the extent practicable, quarterly
quantifiable and measurable objectives and specific targets
to accomplish long-term quantifiable goals specified in the
Strategy; and
``(2) for each year covered by the Strategy, a performance
evaluation plan for each goal listed in the Strategy for each
National Drug Control Program Agency, including--
``(A) specific performance measures for each National Drug
Control Program Agency and each such agency's related
programs and activities;
``(B) annual and, to the extent practicable, quarterly
objectives and targets for each performance measure; and
``(C) an estimate of Federal funding and other resources
needed to achieve each performance objective and target.
``(e) Submission of Revised Strategy.--
``(1) In general.--The President may submit to Congress a
revised National Drug Control Strategy that meets the
requirements of this section--
``(A) at any time, upon a determination of the President,
in consultation with the Director, that the National Drug
Control Strategy in effect is not sufficiently effective; or
``(B) if a new President or Director takes office.
``(2) No submission .--In each year the President does not
submit a National Drug Control Strategy or a revised National
Drug Control Strategy, the Director shall evaluate the
efficacy and appropriateness of the goals of the National
Drug Control Strategy and include a statement affirming the
adequacy of the goals in the performance supplement under
subsection (d).
``(f) Failure of President to Submit National Drug Control
Strategy.--If the President does not submit a National Drug
Control Strategy to Congress in accordance with subsection
(a)(2), not later than five days after the first Monday in
February following the year in which the term of the
President commences, the President shall
[[Page H5309]]
send a notification to the appropriate congressional
committees--
``(1) explaining why the Strategy was not submitted; and
``(2) specifying the date by which the Strategy will be
submitted.
``Sec. 1006. Development of an annual national drug control
assessment
``(a) Timing.--Not later than the first Monday in February
of each year, the Director shall submit to the President,
Congress, and the appropriate congressional committees, a
report assessing the progress of each National Drug Control
Program Agency toward achieving each goal, objective, and
target contained in the National Drug Control Strategy
applicable to the prior fiscal year.
``(b) Process for Development of the Annual Assessment.--
Not later than November 1 of each year, the head of each
National Drug Control Program Agency shall submit, in
accordance with guidance issued by the Director, to the
Director an evaluation of progress by the agency with respect
to the National Drug Control Strategy goals using the
performance measures for the agency developed under this
chapter, including progress with respect to--
``(1) success in achieving the goals of the National Drug
Control Strategy;
``(2) success in reducing domestic and foreign sources of
illegal drugs;
``(3) success in expanding access to and increasing the
effectiveness of substance use disorder treatment;
``(4) success in protecting the borders of the United
States (and in particular the Southwestern border of the
United States) from penetration by illegal narcotics;
``(5) success in reducing crime associated with drug use in
the United States;
``(6) success in reducing the negative health and social
consequences of drug use in the United States; and
``(7) implementation of substance use disorder treatment
and prevention programs in the United States and improvements
in the adequacy and effectiveness of such programs.
``(c) Contents of the Annual Assessment.--The Director
shall include in the annual assessment required under
subsection (a)--
``(1) a summary of each evaluation received by the Director
under subsection (b);
``(2) a summary of the progress of each National Drug
Control Program Agency toward the National Drug Control
Strategy goals of the agency using the performance measures
for the agency developed under this chapter;
``(3) an assessment of the effectiveness of each National
Drug Control Program Agency and program in achieving the
National Drug Control Strategy for the previous year,
including a specific evaluation of whether the applicable
goals, measures, objectives, and targets for the previous
year were met;
``(4) for each National Drug Control Program Agency that
administers grant programs, an evaluation of the
effectiveness of each grant program, including an accounting
of the funds disbursed by the program in the prior year and a
summary of how those funds were used by the grantees and sub-
grantees during that period;
``(5) a detailed accounting of the amount of funds
obligated by each National Drug Control Program Agency in
carrying out the responsibilities of that agency under the
Strategy;
``(6) an assessment of the effectiveness of any Emerging
Threat Response Plan in effect for the previous year,
including a specific evaluation of whether the objectives and
targets were met and reasons for the success or failure of
the previous year's plan;
``(7) a detailed accounting of the amount of funds
obligated during the previous fiscal year for carrying out
the campaign under section 1009(d), including each recipient
of funds, the purpose of each expenditure, the amount of each
expenditure, any available outcome information, and any other
information necessary to provide a complete accounting of the
funds expended; and
``(8) the assessments required under this subsection shall
be based on the Performance Measurement System describe in
subsection (d).
``(d) Performance Measurement System.--The Director shall
include in the annual assessment required under subsection
(a) a national drug control performance measurement system,
that--
``(1) develops annual, 2-year, and 5-year performance
measures, objectives, and targets for each National Drug
Control Strategy goal and objective established for reducing
drug use, availability, and the consequences of drug use;
``(2) describes the sources of information and data that
will be used for each performance measure incorporated into
the performance measurement system;
``(3) identifies major programs and activities of the
National Drug Control Program Agencies that support the goals
and annual objectives of the National Drug Control Strategy;
``(4) evaluates the contribution of demand reduction and
supply reduction activities implemented by each National Drug
Control Program Agency in support of the National Drug
Control Strategy;
``(5) monitors consistency between the drug-related goals,
measures, targets, and objectives of the National Drug
Control Program Agencies and ensures that each agency's goals
and budgets support, and are fully consistent with, the
National Drug Control Strategy; and
``(6) coordinates the development and implementation of
national drug control data collection and reporting systems
to support policy formulation and performance measurement,
including an assessment of--
``(A) the quality of current drug use measurement
instruments and techniques to measure supply reduction and
demand reduction activities;
``(B) the adequacy of the coverage of existing national
drug use measurement instruments and techniques to measure
the illicit drug user population and groups that are at risk
for illicit drug use;
``(C) the adequacy of the coverage of existing national
treatment outcome monitoring systems to measure the
effectiveness of substance use disorder treatment in reducing
illicit drug use and criminal behavior during and after the
completion of substance use disorder treatment; and
``(D) the actions the Director shall take to correct any
deficiencies and limitations identified pursuant to
subparagraphs (A), (B), and (C).
``(e) Modifications.--A description of any modifications
made during the preceding year to the national drug
performance measurement system described in subsection (d)
shall be included in each report submitted under subsection
(a).
``(f) Annual Report on Consultation.--The Director shall
include in the annual assessment required under subsection
(a)--
``(1) a detailed description of how the Office has
consulted with and assisted State, local, and Tribal
governments with respect to the formulation and
implementation of the National Drug Control Strategy and
other relevant issues; and
``(2) a general review of the status of, and trends in,
demand reduction activities by private sector entities and
community-based organizations, including faith-based
organizations, to determine their effectiveness and the
extent of cooperation, coordination, and mutual support
between such entities and organizations and Federal, State,
local, and Tribal government agencies.
``(g) Performance-budget Coordinator.--
``(1) Designation.--The Director shall designate or appoint
a United States Performance-Budget Coordinator to--
``(A) ensure the Director has sufficient information
necessary to analyze the performance of each National Drug
Control Program Agency, the impact Federal funding has had on
the goals in the Strategy, and the likely contributions to
the goals of the Strategy based on funding levels of each
National Drug Control Program Agency, to make an independent
assessment of the budget request of each agency under section
1004;
``(B) advise the Director on agency budgets, performance
measures and targets, and additional data and research needed
to make informed policy decisions under sections 1004 and
1005; and
``(C) other duties as may be determined by the Director
with respect to measuring or assessing performance or agency
budgets.
``(2) Determination of position.--The Director shall
determine whether the coordinator position is a noncareer
appointee in the Senior Executive Service or a career
appointee at the GS-15 level (or equivalent) or above.
``Sec. 1007. Monitoring and evaluation of national drug
control program
``(a) In General.--The Director shall monitor
implementation of the National Drug Control Program and the
activities of the National Drug Control Program Agencies in
carrying out the goals and objectives of the National Drug
Control Strategy including--
``(1) conducting program and performance audits and
evaluations; and
``(2) requesting assistance from the Inspector General of
the relevant agency in such audits and evaluations.
``(b) Accounting of Funds Expended.--(1) Not later than
February 1 of each year, in accordance with guidance issued
by the Director, the head of each National Drug Control
Program Agency shall submit to the Director a detailed
accounting of all funds expended by the agency for National
Drug Control Program activities during the previous fiscal
year and shall ensure such detailed accounting is
authenticated for the previous fiscal year by the Inspector
General for such agency prior to the submission to the
Director as frequently as determined by the Inspector General
but not less frequently that every three years.
``(2) The Director shall submit to Congress not later than
April 1 of each year the information submitted to the
Director under paragraph (1).
``(c) Notification.--The Director shall notify any National
Drug Control Program Agency if its activities are not in
compliance with the responsibilities of the agency under the
National Drug Control Strategy, transmit a copy of each such
notification to the President and the appropriate
congressional committees, and maintain a copy of each such
notification.
``(d) Recommendations.--The Director shall make such
recommendations to the President and the appropriate
congressional committees as the Director determines are
appropriate regarding changes in the organization,
management, and budgets of the National Drug Control Program
Agencies, and changes in the allocation of personnel to and
within those agencies, to implement the policies, goals,
objectives, and priorities established under section
1002(c)(1) and the National Drug Control Strategy.
``(e) Authorization, Development, and Implementation of a
Coordinated Tracking System.--
[[Page H5310]]
``(1) Establishment.--The Director shall establish a
coordinated tracking system of federally-funded initiatives
and grant programs which shall--
``(A) be the central repository of all drug control grants;
``(B) identify duplication, overlap, or gaps in funding to
provide increased accountability of federally-funded grants
for substance use disorder treatment, prevention, and
enforcement;
``(C) identify impediments that applicants currently have
in the grant application process with applicable agencies;
and
``(D) be developed and maintained by the Office with the
support of designated National Drug Control Program Agencies
and any other agency determined by the Director.
``(2) Performance metrics.--The Director shall identify
metrics and achievable goals for grant recipients in
furtherance of the Strategy. Such metrics shall be used to
measure how effective each federally funded initiative is in
achieving the objectives of the Strategy and to enable
comparisons of federally funded initiatives to identify those
that are the most cost effective.
``(3) Grant application standardization.--To reduce the
administrative burden on grant applicants and improve
oversight of Federal funds, the Director, in consultation
with the head of each National Drug Control Program Agency,
shall develop a plan for coordinating and standardizing drug
control grant application processes and develop a joint
application to be used by all National Drug Control Program
Agencies.
``(4) Central portal.--The Director shall maintain on the
public, electronic portal of the Office a list all drug
control grant programs available in a central location. The
head of each National Drug Control Program Agency shall
provide a complete list of all drug control program grant
programs to the Director and annually update such list.
``(5) Report to congress.--The Director shall include in
the assessment submitted to Congress under section 1006 an
assessment on progress under this section.
``Sec. 1008. Coordination and oversight of the national drug
control program
``(a) In General.--The Director shall coordinate and
oversee the implementation by the National Drug Control
Program Agencies of the policies, goals, objectives, and
priorities established under section 1002(c)(1) and the
fulfillment of the responsibilities of such agencies under
the National Drug Control Strategy and make recommendations
to National Drug Control Program Agency heads with respect to
implementation of National Drug Control Programs.
``(b) Detailing Employees to Other Agencies.--
``(1) Request.--The Director may request the head of an
agency or program of the Federal Government to place agency
personnel who are engaged in drug control activities on
temporary detail to another agency in order to implement the
National Drug Control Strategy.
``(2) Agency compliance.--The head of the agency shall
comply with any request made under paragraph (1).
``(3) Maximum number of detailees.--The maximum number of
personnel who may be detailed to another agency (including
the Office) under this subsection during any fiscal year is--
``(A) for the Department of Defense, 50; and
``(B) for any other agency, 10.
``(c) Directing Federal Funding.--The Director may transfer
funds made available to a National Drug Control Program
Agency for National Drug Control Strategy programs and
activities to another account within such agency or to
another National Drug Control Program Agency for National
Drug Control Strategy programs and activities, except that--
``(1) the authority under this subsection may be limited in
an annual appropriations Act or other provision of Federal
law;
``(2) the Director may exercise the authority under this
subsection only with the concurrence of the head of each
affected agency;
``(3) in the case of an interagency transfer, the total
amount of transfers under this subsection may not exceed 3
percent of the total amount of funds made available for
National Drug Control Strategy programs and activities to the
agency from which those funds are to be transferred;
``(4) funds transferred to an agency under this subsection
may only be used to increase the funding for programs or
activities authorized by law;
``(5) the Director shall--
``(A) submit to the appropriate congressional committees
and any other applicable committee of jurisdiction, a
reprogramming or transfer request in advance of any transfer
under this subsection in accordance with the regulations of
each affected agency; and
``(B) annually submit to the appropriate congressional
committees a report describing the effect of all transfers of
funds made pursuant to this subsection or section 1004(f)
during the 12-month period preceding the date on which the
report is submitted; and
``(6) funds may only be used for--
``(A) expansion of demand reduction activities;
``(B) interdiction of illicit drugs on the high seas, in
United States territorial waters, and at United States ports
of entry by officers and employees of National Drug Control
Program Agencies and domestic and foreign law enforcement
officers;
``(C) accurate assessment and monitoring of international
drug production and interdiction programs and policies;
``(D) activities to facilitate and enhance the sharing of
domestic and foreign intelligence information among National
Drug Control Program Agencies related to the production and
trafficking of drugs in the United States and foreign
countries;
``(E) activities to prevent the diversion of prescription
drugs for illicit use; and
``(F) research related to any of these activities.
``(d) Directing Federal Funding to Respond to Emerging
Threats.--
``(1) In general.--The Director may transfer funds made
available to a National Drug Control Program Agency for
National Drug Control Strategy programs and activities to
another account within such agency or to another National
Drug Control Program Agency for National Drug Control
Strategy programs and activities to implement the provisions
of a plan developed under section 1009, except that--
``(A) the authority under this subsection may be limited in
an annual appropriations Act or other provision of Federal
law;
``(B) the Director may exercise the authority under this
subsection only with the concurrence of the head of each
affected agency;
``(C) in the case of an interagency transfer, the total
amount of transfers under this subsection may not exceed 10
percent of the total amount of funds made available for
National Drug Control Strategy programs and activities to the
agency from which those funds are to be transferred;
``(D) funds transferred to an agency under this subsection
may only be used to increase the funding for programs or
activities authorized by law;
``(E) no transfer of funds under this subsection may result
in a reduction in total Federal expenditures for substance
use disorder treatment;
``(F) the Director shall--
``(i) submit to the appropriate congressional committees
and any other applicable committee of jurisdiction, a
reprogramming or transfer request in advance of any transfer
under this subsection in accordance with the regulations of
each affected agency; and
``(ii) annually submit to the appropriate congressional
committees a report describing the effect of all transfers of
funds made pursuant to this subsection or section 1004(f)
during the 12-month period preceding the date on which the
report is submitted; and
``(G) funds may only be used for--
``(i) expansion of demand reduction activities;
``(ii) interdiction of illicit drugs on the high seas, in
United States territorial waters, and at United States ports
of entry by officers and employees of National Drug Control
Program Agencies and domestic and foreign law enforcement
officers;
``(iii) accurate assessment and monitoring of international
drug production and interdiction programs and policies;
``(iv) activities to facilitate and enhance the sharing of
domestic and foreign intelligence information among National
Drug Control Program Agencies related to the production and
trafficking of drugs in the United States and foreign
countries;
``(v) activities to prevent the diversion of prescription
drugs for illicit use; and
``(vi) research related to any of these activities.
``(2) Inadequacy of transfer.--In the event the authority
under this subsection is inadequate to implement the
provisions of a plan developed under section 1009, the
Director shall submit a request for funding to the
appropriate congressional committees within 30 days after the
date on which the Director determines there is a need for
additional funding.
``(e) Fund Control Notices.--
``(1) In general.--The Director may issue to the head of a
National Drug Control Program Agency a fund control notice to
ensure compliance with the National Drug Control Program
Strategy. A fund control notice may direct that all or part
of an amount appropriated to the National Drug Control
Program Agency account be obligated by--
``(A) months, fiscal year quarters, or other time periods;
and
``(B) activities, functions, projects, or object classes.
``(2) Unauthorized obligation or expenditure prohibited.--
An officer or employee of a National Drug Control Program
Agency shall not make or authorize an expenditure or
obligation contrary to a fund control notice issued by the
Director.
``(3) Disciplinary action for violation.--In the case of a
violation of paragraph (2) by an officer or employee of a
National Drug Control Program Agency, the head of the agency,
upon the request of and in consultation with the Director,
may subject the officer or employee to appropriate
administrative discipline, including, when circumstances
warrant, suspension from duty without pay or removal from
office.
``(4) Congressional notice.--Not later than 5 days after
issuance of a fund control notice, the Director shall submit
a copy of such fund control notice to the appropriate
congressional committees and make such notice publicly
available.
``(5) Restrictions.--The Director may not issue a fund
control notice to direct that all or part of an amount
appropriated to the National Drug Control Program Agency
account be obligated, modified, or altered in any manner
contrary, in whole or in part, to a specific appropriation or
statute.
[[Page H5311]]
``(f) Exclusions.--The authorities described under
subsections (c), (d), and (e) do not apply to any program
under subchapter II or III.
``(g) Foreign Assistance Act Participation.--The Director
may participate in the drug certification process pursuant to
section 490 of the Foreign Assistance Act of 1961 (22 U.S.C.
2291j) and section 706 of the Department of State
Authorization Act for Fiscal Year 2003 (22 U.S.C. 229j-l).
``(h) Certifications of Policy Changes to Director.--
``(1) In general.--Subject to paragraph (2), the head of a
National Drug Control Program Agency shall, unless exigent
circumstances require otherwise, notify the Director in
writing regarding any proposed change in policies relating to
the activities of that agency under the National Drug Control
Program prior to implementation of such change. The Director
shall promptly review such proposed change and certify to the
head of that agency in writing whether such change is
consistent with the National Drug Control Strategy.
``(2) Exception.--If prior notice of a proposed change
under paragraph (1) is not practicable--
``(A) the head of the National Drug Control Program Agency
shall notify the Director of the proposed change as soon as
practicable; and
``(B) upon such notification, the Director shall review the
change and certify to the head of that agency in writing
whether the change is consistent with the National Drug
Control Strategy.
``(i) Work in Conjunction With Assistant for National
Security Affairs.--The Director shall, in any matter
affecting national security interests, work in conjunction
with the Assistant to the President for National Security
Affairs.
``(j) Authorities Not Derogated.--Nothing in this chapter
shall be construed as derogating the authorities and
responsibilities of the head of any agency, the Director of
National Intelligence, or the Director of the Central
Intelligence Agency contained in the National Security Act of
1947 (50 U.S.C. 401 et seq.), the Central Intelligence Agency
Act of 1949 (50 U.S.C. 403a et seq.), or any other law.
``Sec. 1009. Emerging threats task force, plan, campaign
``(a) Emerging Threats Task Force.--
``(1) Emerging and continuing threats coordinator.--The
Director shall designate or appoint a United States Emerging
and Continuing Threats Coordinator to perform the duties of
that position described in this section and such other duties
as may be determined by the Director. The Director shall
determine whether the coordinator position is a noncareer
appointee in the Senior Executive Service or a career
appointee at the GS-15 level (or equivalent) or above.
``(2) Establishment and monitoring.--The Emerging and
Continuing Threats Coordinator (referred to in this section
as the `Coordinator') shall monitor evolving and emerging
drug threats in the United States and shall serve as Chair of
an Emerging Threats Task Force (in this section, referred to
as the `task force'). The Director shall appoint other
members of the task force, which shall include--
``(A) representatives from National Drug Control Program
Agencies or other agencies;
``(B) representatives from State, local, and Tribal
governments;
``(C) the Director of the National Drug Control Fusion
Center established in section 1013; and
``(D) representatives from other entities as determined to
be necessary by the Director.
``(3) Information review and sharing.--
``(A) In general.--The task force shall disseminate and
facilitate the sharing with Federal, State, local, and Tribal
officials and other entities as determined by the Director of
pertinent information and data relating to the following:
``(i) Recent trends in drug supply and demand.
``(ii) Fatal and nonfatal overdoses.
``(iii) Demand for and availability of evidence-based
substance use disorder treatment, including the extent of the
unmet treatment need, and treatment admission trends.
``(iv) Recent trends in drug interdiction, supply, and
demand from State, local, and Tribal law enforcement
agencies.
``(v) Other subject matter as determined necessary by the
Director.
``(B) Contract, agreement, and other authority.--The
Director may award contracts, enter into interagency
agreements, manage individual projects, and conduct other
activities in support of the identification of emerging drug
threats and in support of the development, implementation,
and assessment of any Emerging Threat Response Plan.
``(C) Data analysis activities.--In support of the task
force, the National Drug Control Fusion Center is authorized
to conduct and provide to the task force the results of data
analysis activities that the task force requests to aid in
their review of recent trends in the data disseminated under
subparagraph (A).
``(4) Criteria to identify emerging drug threats.--Not
later than 60 days after the date on which a task force first
meets, the task force shall develop and recommend to the
Director criteria to be used to identify an emerging drug
threat or the termination of an emerging drug threat
designation based on information gathered by the task force
in paragraph (2), statistical data, and other evidence.
``(5) Meetings.--The task force shall meet in person not
less frequently than quarterly and at additional meetings if
determined to be necessary by and at the call of the Chair
to--
``(A) identify and discuss evolving and emerging drug
trends in the United States using the criteria established in
paragraph (3);
``(B) assist in the formulation of any plan described in
subsection (c);
``(C) oversee implementation of the plan described in
subsection (c); and
``(D) provide such other advice to the Coordinator and
Director concerning strategy and policies for emerging drug
threats and trends as the task force determines to be
appropriate.
``(b) Designation.--
``(1) In general.--The Director, in consultation with the
Coordinator, the task force, and the head of each National
Drug Control Program Agency, may designate an emerging drug
threat in the United States.
``(2) Standards for designation.--The Director, in
consultation with the Coordinator, shall promulgate and make
publicly available standards by which a designation under
paragraph (1) and the termination of such designation may be
made. In developing such standards, the Director shall
consider the recommendations of the task force and other
criteria the Director considers to be appropriate.
``(3) Public statement required.--The Director shall
publish a public written statement on the portal of the
Office explaining the designation of an emerging drug threat
or the termination of such designation and shall notify the
appropriate congressional committees of the availability of
such statement when a designation or termination of such
designation has been made.
``(c) Plan.--
``(1) Public availability of plan.--Not later than 60 days
after making a designation under subsection (b), the Director
shall publish and make publicly available an Emerging Threat
Response Plan and notify the President and the appropriate
congressional committees of such plan's availability.
``(2) Timing.--Not less frequently than every 90 days after
the date on which the plan is published under paragraph (1),
the Director shall update the plan and report on
implementation of the plan, until the Director issues the
public statement required under subsection (b)(3) to
terminate the emerging drug threat designation.
``(3) Contents of an emerging threat response plan.--The
Director shall include in the plan--
``(A) a comprehensive strategic assessment of the emerging
drug threat, including the current availability of, demand
for, and effectiveness of evidence-based prevention,
treatment, and enforcement programs and efforts to respond to
the emerging drug threat;
``(B) comprehensive, research-based, long-range,
quantifiable goals for addressing the emerging drug threat,
including for reducing the supply of the drug designated as
the emerging drug threat and for expanding the availability
and effectiveness of evidence-based substance use disorder
treatment and prevention programs to reduce the demand for
the emerging drug threat;
``(C) performance measures pertaining to the plan's goals,
including quantifiable and measurable objectives and specific
targets;
``(D) the level of funding needed to implement the plan,
including whether funding is available to be reprogrammed or
transferred to support implementation of the plan or whether
additional appropriations are necessary to implement the
plan;
``(E) an implementation strategy for the education and
public awareness campaign under subsection (d), including
goals as described under subparagraph (B) and performance
measures, objectives, and targets, as described under
subparagraph (C); and
``(F) any other information necessary to inform the public
of the status, progress, or response of an emerging drug
threat.
``(4) Implementation.--
``(A) In general.--Not later than 90 days after the date on
which a designation is made under subsection (b), the
Director, in consultation with the President, the appropriate
congressional committees, and the head of each National Drug
Control Program Agency, shall issue guidance on
implementation of the plan described in this subsection to
the National Drug Control Program Agencies and any other
relevant agency determined to be necessary by the Director.
``(B) Coordinator's responsibilities.--The Coordinator
shall--
``(i) direct the implementation of the plan among the
agencies identified in the plan, State, local, and Tribal
governments, and other relevant entities;
``(ii) facilitate information-sharing between agencies
identified in the plan, State, local, and Tribal governments,
and other relevant entities; and
``(iii) monitor implementation of the plan by coordinating
the development and implementation of collection and
reporting systems to support performance measurement and
adherence to the plan by agencies identified in plan, where
appropriate.
``(C) Reporting.--Not later than 180 days after the date on
which a designation is made under subsection (b) and in
accordance
[[Page H5312]]
with paragraph (2)(C), the head of each agency identified in
the plan shall submit to the Coordinator a report on
implementation of the plan.
``(d) Education and Public Awareness Campaign for Emerging
Drug Threats.--
``(1) In general.--Not later than 90 days after the date on
which a designation is made under subsection (b), the
Director shall, to the extent feasible and appropriate,
establish and implement an evidence-based substance use
prevention education and public awareness campaign to inform
the public about the dangers of any drug designated as an
emerging drug threat. Such campaign shall--
``(A) educate the public about the dangers of such drug,
including patient and family education about the
characteristics and hazards of such drug and methods to
safeguard against such dangers, including the safe disposal
of such drug;
``(B) support evidence-based prevention programs targeting
audiences' attitudes, perceptions, and beliefs concerning
substance use and intentions to initiate or continue such
use;
``(C) increase awareness of the negative consequences of
drug use;
``(D) encourage individuals affected by substance use
disorders to seek treatment and provide such individuals with
information on how to recognize addiction issues, what forms
of evidence-based treatment options are available, and how to
access such treatment; and
``(E) combat the stigma of addiction and substance use
disorders, including the stigma of treating such disorders
with medication-assisted treatment therapies.
``(2) Consultation.--For the planning of the campaign under
paragraph (1), the Director shall consult with--
``(A) the head of any appropriate National Drug Control
Program Agency to obtain advice on evidence-based scientific
information for policy, program development, and evaluation;
``(B) experts in evidence-based media campaigns, education,
evaluation, and communication;
``(C) experts on the designated drug;
``(D) State, local, and Tribal government officials and
relevant agencies;
``(E) the public;
``(F) appropriate congressional committees; and
``(G) any other affected person, as determined by the
Director.
``(3) Gifts and donations.--
``(A) In general.--The Director may accept gifts and
donations (in cash or in kind, including voluntary and
uncompensated services or property), which shall be available
until expended, for the purpose of supporting the education
and public awareness campaign authorized in this section,
including the media campaign.
``(B) Ethics guidelines.--The Director shall establish
written guidelines setting forth the criteria to be used in
determining whether a gift or donation should be declined
under this section because the acceptance of the gift or
donation would--
``(i) reflect unfavorably upon the ability of the Director
or the Office, or any employee of the Office, to carry out
responsibilities or official duties under this chapter in a
fair and objective manner; or
``(ii) compromise the integrity or the appearance of
integrity of programs or services provided under this chapter
or of any official involved in those programs or services.
``(4) Implementation.--
``(A) In general.--For any campaign established under this
subsection, the Director shall ensure the following:
``(i) Implementation is evidence-based, meets accepted
standards for public awareness campaigns, and uses available
resources in a manner to make the most progress toward
achieving the goals identified in the Emerging Threats
Response Plan and the requirements of paragraph (1).
``(ii) Information disseminated through the campaign is
accurate.
``(iii) The Director approves the strategy of the campaign,
all material distributed through the campaign, and the use of
any Federal funds used for the campaign.
``(iv) The campaign is designed using strategies found to
be most effective at achieving such goals and requirements of
paragraph (1), which may include--
``(I) a media campaign, as described in subparagraph (B);
``(II) local, regional, or population specific messaging;
``(III) establishing partnerships and promoting
coordination among community stakeholders, including public,
nonprofit organizations, and for profit entities;
``(IV) providing support, training, and technical
assistance to establish and expand school and community
prevention programs;
``(V) creating websites to publicize and disseminate
information;
``(VI) conducting outreach and providing educational
resources for parents;
``(VII) establishing State or regional advisory councils to
provide input and recommendations to raise awareness
regarding the drug designated as an emerging drug threat;
``(VIII) collaborating with law enforcement; and
``(IX) support for school-based public health education
classes to improve teen knowledge about the effects of such
designated drug.
``(B) Media campaign.--Any campaign implemented under this
subsection may include a media component, which--
``(i) shall be designed to prevent the use of the drug
designated as an emerging drug threat and to achieve the
goals and requirements of paragraph (1);
``(ii) shall be carried out through competitively awarded
contracts to entities providing for the professional
production and design of such campaign; and
``(iii) may include the use of television, radio, Internet,
social media, and other commercial marketing venues and may
be targeted to specific age groups based on peer-reviewed
social research.
``(C) Required notice for communication from the office.--
Any communication, including an advertisement, paid for or
otherwise disseminated by the Office directly or through a
contract awarded by the Office shall include a prominent
notice informing the audience that the communication was paid
for by of the Office.
``(5) Evaluation.--
``(A) Performance evaluation.--The Director shall include
an evaluation of the campaign in the annual assessment under
section 1006, which shall include the following:
``(i) A performance evaluation of the campaign, including
progress toward meeting the goals, objectives, measures, and
targets identified in the Emerging Threats Response Plan.
``(ii) A description of all policies and practices to
eliminate the potential for waste, fraud, abuse, and to
ensure Federal funds are used responsibly.
``(iii) A list of all contracts or other agreements entered
into to implement the campaign.
``(iv) The results of any financial audit of the campaign.
``(v) A description of any evidence used to develop the
campaign.
``(vi) The sources and amount of each gift or donation
accepted by the Office, and the source and amount of each
gift or donation accepted by a contractor to be used in its
performance of a contract for the campaign.
``(B) Independent evaluation.--Not later than 180 days
after establishing a campaign under paragraph (1) and not
less than frequently than every two years thereafter, the
Director shall--
``(i) designate an independent entity to evaluate the
effectiveness of the campaign with meeting the goals
established in the Emerging Threat Response Plan and the
requirements of paragraph (1); and
``(ii) submit the results of the independent evaluation to
the appropriate congressional committees.
``(6) Funding prohibitions.--None of the amounts made
available under this subsection may be obligated for any of
the following:
``(A) To supplant current anti-drug community-based
coalitions.
``(B) To supplant pro bono public service time donated by
national and local broadcasting network for other public
services campaigns.
``(C) For partisan political purposes, or express advocacy
in support of or to defeat any clearly identified candidate,
clearly identified ballot initiative, or clearly identified
legislative or regulatory proposal.
``(D) For any advocacy in support of any particular
company, industry association, or advocacy group or the
explicit policy positions held by such groups.
``(E) To direct any individuals to a specific type of
substance use disorder treatment, treatment facility, medical
provider, or form of medication assisted treatment.
``(F) To fund any advertising that features any elected
officials, persons seeking elected office, cabinet level
officials, or other Federal officials employed pursuant to
section 213 of Schedule C of title 5, Code of Federal
Regulations.
``(e) Authorization of Appropriations.--There is authorized
to be appropriated to the Office to carry out this section,
$25,000,000 for each of fiscal years 2019 through 2023.
``Sec. 1010. National and international coordination
``(a) Dissemination of Research and Information to
States.--The Director shall ensure that drug control research
and information is effectively disseminated by National Drug
Control Program Agencies to State and local governments and
nongovernmental entities involved in demand reduction by--
``(1) encouraging formal consultation between any such
agency that conducts or sponsors research, and any such
agency that disseminates information in developing research
and information product development agendas;
``(2) encouraging such agencies (as appropriate) to develop
and implement dissemination plans that specifically target
State and local governments and nongovernmental entities
involved in demand reduction; and
``(3) supporting the substance abuse information
clearinghouse administered by the Assistant Secretary for
Mental Health and Substance Use and established in section
501(d)(16) of the Public Health Service Act by--
``(A) encouraging all National Drug Control Program
Agencies to provide all appropriate and relevant information;
and
``(B) supporting the dissemination of information to all
interested entities.
``(b) Standards.--
``(1) Development.--The Director shall coordinate the
development of evidence-based
[[Page H5313]]
standards developed by National Drug Control Program Agencies
and other relevant agencies and non-Federal entities to
State, local, and Tribal governments and nongovernmental
entities related to drug control policies, practices, and
procedures, such as the investigation of drug-related deaths,
by--
``(A) encouraging appropriate agencies and State, local,
and Tribal governments to develop data standards for drug
control practices and procedures and related statistical
data;
``(B) encouraging information sharing between appropriate
agencies and State, local, and Tribal governments of relevant
drug control information and data;
``(C) establishing a working group of agencies, State,
local, and Tribal governments, and other relevant
stakeholders to discuss and develop such standards; and
``(D) facilitating collaboration among agencies, non-
Federal entities, States, local, and Tribal governments, and
nongovernmental agencies.
``(2) Implementation.--The Director shall promote the
implementation of the standards described in paragraph (1)
by--
``(A) encouraging adoption by providing the standards to
State and local governments through the internet, annual
publications or periodicals, and other widely-disseminated
means; and
``(B) facilitating the use and dissemination of such
standards among State and local governments by--
``(i) providing technical assistance to State, local, and
Tribal governments seeking to adopt or implement such
standards; and
``(ii) coordinating seminars and training sessions for
State, local, and Tribal governments seeking to adopt or
implement such standards.
``(c) Private Sector.--
``(1) In general.--The Director or the head of a National
Drug Control Program (as designated by the Director) shall
coordinate with the private sector to promote private
research and development of medications to treat or prevent
addiction, including research and development for non-
addictive pain management medication, abuse deterrent
formulations, medication-assisted treatment, and other
addiction research determined to be necessary by the Director
by--
``(A) encouraging the sharing of information regarding
evidence-based treatment addiction findings and related data
between agencies and the private sector, as appropriate;
``(B) encouraging collaboration between appropriate
agencies and the private sector; and
``(C) providing private sector entities with relevant
statistical data and information to enhance research as
permissible.
``(2) Working group.--The Director may establish a working
group of National Drug Control Program Agencies, State,
local, and Tribal governments, and the private sector
stakeholders to discuss and disseminate best practices,
research and development, and other related issues, as
appropriate.
``(d) Model Acts Program.--
``(1) In general.--The Director shall provide for or shall
enter into an agreement with a nonprofit organization to--
``(A) advise States on establishing laws and policies to
address illicit drug use issues; and
``(B) revise such model State drug laws and draft
supplementary model State laws to take into consideration
changes in illicit drug use issues in the State involved.
``(2) Authorization of appropriations.--There is authorized
to be appropriated to carry out this subsection $1,250,000
for each of fiscal years 2019 through 2023.
``(e) Drug Court Training and Technical Assistance
Program.--
``(1) Grants authorized.--The Director may make a grant to
a nonprofit organization for the purpose of providing
training and technical assistance to drug courts.
``(2) Authorization of appropriations.--There is authorized
to be appropriated to carry out this subsection $2,000,000
for each of fiscal years 2019 through 2023.
``(f) International Coordination.--The Director may
facilitate international drug control coordination efforts.
``(g) State, Local, and Tribal Affairs Coordinator.--The
Director shall designate or appoint a United States State,
Local, and Tribal Affairs Coordinator to perform the duties
of the Office outlined in this section and section 1005 and
such other duties as may be determined by the Director with
respect to coordination of drug control efforts between
agencies and State, local, and Tribal governments. The
Director shall determine whether the coordinator position is
a noncareer appointee in the Senior Executive Service or a
career appointee at the GS-15 level (or equivalent) or above.
``Sec. 1011. Interdiction
``(a) United States Interdiction Coordinator.--
``(1) In general.--The Director shall designate or appoint
a noncareer appointee in the Senior Executive Service or a
career appointee at the GS-15 level (or equivalent) or above
as the United States Interdiction Coordinator to perform the
duties of that position described in paragraph (2) and such
other duties as may be determined by the Director with
respect to coordination of efforts to interdict illicit drugs
from entering the United States.
``(2) Responsibilities.--The United States Interdiction
Coordinator shall be responsible to the Director for--
``(A) coordinating the interdiction activities of the
National Drug Control Program Agencies to ensure consistency
with the National Drug Control Strategy;
``(B) on behalf of the Director, developing and issuing, on
or before September 1 of each year and in accordance with
paragraph (4), a National Interdiction Command and Control
Plan to ensure the coordination and consistency described in
subparagraph (A);
``(C) assessing the sufficiency of assets committed to
illicit drug interdiction by the relevant National Drug
Control Program Agencies; and
``(D) advising the Director on the efforts of each National
Drug Control Program Agency to implement the National
Interdiction Command and Control Plan.
``(3) Staff.--The Director shall assign such permanent
staff of the Office as he considers appropriate to assist the
United States Interdiction Coordinator to carry out the
responsibilities described in paragraph (2), and may request
that appropriate National Drug Control Program Agencies
detail or assign staff to assist in carrying out such
activities.
``(4) National interdiction command and control plan.--
``(A) Purposes.--The National Interdiction Command and
Control Plan--
``(i) shall set forth the Government's strategy for drug
interdiction;
``(ii) shall state the specific roles and responsibilities
of the relevant National Drug Control Program Agencies for
implementing that strategy; and
``(iii) shall identify the specific resources required to
enable the relevant National Drug Control Program Agencies to
implement that strategy.
``(B) Consultation with other agencies.--Before the
submission of the National Drug Control Strategy or annual
supplement required under section 1005(d), as applicable, the
United States Interdiction Coordinator shall issue the
National Interdiction Command and Control Plan, in
consultation with the other members of the Interdiction
Committee described in subsection (b).
``(C) Report to congress.--On or before September 1 of each
year, the Director, through the United States Interdiction
Coordinator, shall provide to the appropriate congressional
committees, to the Committee on Armed Services and the
Committee on Homeland Security of the House of
Representatives, and to the Committee on Homeland Security
and Governmental Affairs and the Committee on Armed Services
of the Senate, a report that--
``(i) includes--
``(I) a copy of that year's National Interdiction Command
and Control Plan;
``(II) information for the previous 10 years regarding the
number and type of seizures of drugs by each National Drug
Control Program Agency conducting drug interdiction
activities and statistical information on the geographic
areas of such seizures; and
``(III) information for the previous 10 years regarding the
number of air and maritime patrol hours undertaken by each
National Drug Control Program Agency conducting drug
interdiction activities and statistical information on the
geographic areas in which such patrol hours took place; and
``(ii) may include recommendations about changes to
existing agency authorities or laws governing interagency
relationships.
``(D) Classified annex.--The report submitted pursuant to
subparagraph (C) may include a classified annex.
``(b) Interdiction Committee.--
``(1) In general.--The Interdiction Committee shall meet
to--
``(A) discuss and resolve issues related to the
coordination, oversight, and integration of international,
border, and domestic drug interdiction efforts in support of
the National Drug Control Strategy;
``(B) review the annual National Interdiction Command and
Control Plan, and provide advice to the Director and the
United States Interdiction Coordinator concerning that plan;
and
``(C) provide such other advice to the Director concerning
drug interdiction strategy and policies as the committee
determines is appropriate.
``(2) Chair.--The Director shall designate one of the
members of the Interdiction Committee to serve as Chair.
``(3) Meetings.--The members of the Interdiction Committee
shall meet, in person and not through any delegate or
representative, at least once per calendar year, before June
1. At the call of the Director or the Chair, the Interdiction
Committee may hold additional meetings, which shall be
attended by the members in person, or through such delegates
or representatives as the members may choose.
``(4) Report.--Not later than September 30 of each year,
the Chair of the Interdiction Committee shall submit to the
Director and to the appropriate congressional committees a
report describing the results of the meetings and any
significant findings of the committee during the previous 12
months. Such report may include a classified annex.
``Sec. 1012. Treatment coordinator
``(a) United States Treatment Coordinator.--
``(1) In general.--The Director shall designate or appoint
a noncareer appointee in the Senior Executive Service or a
career appointee at the GS-15 level (or equivalent) or above
as the United States Treatment Coordinator to perform the
responsibilities of that position described in paragraph (2)
and
[[Page H5314]]
such other duties as may be determined by the Director with
respect to coordination of efforts to expand the availability
of substance use disorder treatment with the goal of
eliminating the unmet treatment need.
``(2) Responsibilities.--The United States Treatment
Coordinator shall be responsible to the Director for--
``(A) coordinating the activities of the National Drug
Control Program Agencies undertaken to expand the
availability of evidence-based substance use disorder
treatment to ensure consistency with the National Drug
Control Strategy;
``(B) on behalf of the Director, developing and issuing, on
or before September 1 of each year and in accordance with
paragraph (4), a National Treatment Plan to ensure the
coordination and consistency described in subparagraph (A);
``(C) assessing the sufficiency of Federal resources
directed to substance use disorder treatment by the relevant
National Drug Control Program Agencies;
``(D) encouraging the adoption by all substance use
disorder treatment providers of evidence-based standards to
guide all aspects of treatment provided; and
``(E) advising the Director on the efforts of each National
Drug Control Program Agency to implement the National
Treatment Plan.
``(3) Staff.--The Director shall assign such permanent
staff of the Office of the United States Treatment
Coordinator as the Director determines to be appropriate to
assist the United States Treatment Coordinator to carry out
the responsibilities described in paragraph (2), and may
request that appropriate National Drug Control Program
Agencies detail or assign staff to assist in carrying out
such responsibilities.
``(4) National treatment plan.--
``(A) Purposes.--The National Treatment Plan--
``(i) shall identify the unmet need for treatment for
evidence-based substance use disorders and set forth the
Government's strategy for closing the gap between available
and needed treatment through all sources;
``(ii) shall describe the specific roles and
responsibilities of the relevant National Drug Control
Program Agencies for implementing that strategy;
``(iii) shall identify the specific resources required to
enable the relevant National Drug Control Program Agencies to
implement that strategy;
``(iv) shall identify the resources, including private
sources, required to eliminate the unmet need for evidence-
based substance use disorder treatment; and
``(v) may include recommendations about changes to existing
agency authorities or laws governing interagency
relationships.
``(B) Consultation with other agencies.--Before the
submission of the National Treatment Strategy or annual
supplement required under section 1005(d), as applicable, the
United States Treatment Coordinator shall issue the National
Treatment Plan, in consultation with the other members of the
Treatment Committee described in subsection (b).
``(C) Report to congress.--On or before September 1 of each
year, the Director, through the United States Treatment
Coordinator, shall provide to the appropriate congressional
committees a report that includes a copy of that year's
National Treatment Plan.
``(b) Treatment Committee.--
``(1) In general.--The Treatment Committee shall meet to--
``(A) review and discuss the adequacy of evidence-based
substance use disorder treatment as well as the unmet need
for treatment;
``(B) review and discuss the status of the implementation
of the National Treatment Plan; and
``(C) provide such other advice to the Director concerning
substance use disorder treatment initiatives as the committee
determines is appropriate.
``(2) Chair.--The Director shall designate one of the
members of the Treatment Committee to serve as Chair.
``(3) Meetings.--The members of the Treatment Committee
shall meet, in person and not through any delegate or
representative, at least once per calendar year, before June
1. At the call of the Director or the Chair, the Treatment
Committee may hold additional meetings, which shall be
attended by the members in person, or through such delegates
or representatives as the members may choose.
``(4) Report.--Not later than September 30 of each year,
the Chair of the Treatment Committee shall submit to the
Director and to the appropriate congressional committees a
report describing the results of the meetings and any
significant findings of the committee during the previous 12
months. Such report may include a classified annex.
``Sec. 1013. Critical information coordination
``(a) National Drug Control Fusion Center.--
``(1) Establishment.--The Director shall, in consultation
with the head of each National Drug Control Program Agency,
designate an agency to establish a National Drug Control
Fusion Center (referred to in this section as the `Center').
The Center shall operate under the authority of the Director
and shall work with the National Drug Control Program
Agencies to collect, compile, analyze, and facilitate the
sharing of data on the use of illicit drugs, treatment for
substance use disorder, and interdiction of illicit drugs.
The Center shall be considered a `statistical agency or
unit', as that term is defined in section 502 of the
Confidential Information Protection and Statistical
Efficiency Act of 2002 (44 U.S.C. 3501 note) and shall have
the necessary independence to ensure any data or information
acquired by an agency under a pledge of confidentiality and
for exclusively statistical purposes is used exclusively for
statistical purposes.
``(2) Center director.--There shall be at the head of the
Center a Center Director who shall be appointed by the
Director from among individuals qualified and distinguished
in data governance and statistical analysis.
``(3) Data compilation.--The Director, acting through the
Center Director, shall do the following:
``(A) Coordinate data collection activities among the
National Drug Control Program Agencies.
``(B) Collect information not otherwise collected by
National Drug Control Program Agencies as necessary to inform
the National Drug Control Strategy.
``(C) Compile and analyze any data required to be collected
under this chapter.
``(D) Disseminate technology, as appropriate, to States and
local jurisdictions to enable or improve the collection of
data on drug use, including the recordation of the occurrence
of fatal and non-fatal drug overdoses.
``(E) Compile information collected by National Drug
Control Program Agencies on grants issued through any
National Drug Control Program, including for any grant the
following:
``(i) The recipient.
``(ii) The amount.
``(iii) The intended purpose.
``(iv) Any evidence of the efficacy of the outcomes
achieved by the program funded through the grant.
``(v) Any assessments of how the grant met its intended
purpose.
``(4) Toxicology screening.--
``(A) Establishment.--The Center Director may establish a
toxicology screening program that engages in--
``(i) secondary analysis of urine samples that would
otherwise be discarded by--
``(I) hospitals and substance use disorder treatment
programs;
``(II) correctional facilities, booking sites, probation
programs, drug courts, and related facilities; and
``(III) coroners and medical examiners; and
``(ii) analysis of other physical samples, as determined by
the Center Director to be valuable for understanding the
prevalence of any illicit drug.
``(B) De-identification of information.--The Center
Director shall ensure that no samples have any personally
identifiable information prior to collection.
``(C) Limitation on use.--No data obtained from analysis
conducted under this paragraph may be used as evidence in any
proceeding.
``(D) State program.--The Center Director may establish a
program that enables States and local jurisdictions to submit
up to 20 urine samples per year for toxicology analysis for
the purposes of identifying substances present in individuals
who have suffered fatal drug overdoses.
``(5) Authority to contract.--The Director may award
contracts, enter into interagency agreements, manage
individual projects, and conduct other operational activities
under this subsection.
``(b) Critical Drug Control Information and Evidence
Plan.--
``(1) In general.--Not later than the first Monday in
February of each year, the Director shall submit to Congress
a systematic plan for increasing data collection to enable
real-time surveillance of drug control threats, developing
analysis and monitoring capabilities, and identifying and
addressing policy questions relevant to the National Drug
Control Policy, Strategy, and Program. Such plan shall be
made available on the public online portal of the Office,
shall cover at least a 4-year period beginning with the first
fiscal year following the fiscal year in which the plan is
submitted and published, and contain the following:
``(A) A list of policy-relevant questions for which the
Director and each National Drug Control Program Agency
intends to develop evidence to support the National Drug
Control Program and Strategy.
``(B) A list of data the Director and each National Drug
Control Program Agency intends to collect, use, or acquire to
facilitate the use of evidence in drug control policymaking
and monitoring.
``(C) A list of methods and analytical approaches that may
be used to develop evidence to support the National Drug
Control Program and Strategy and related policy.
``(D) A list of any challenges to developing evidence to
support policymaking, including any barriers to accessing,
collecting, or using relevant data.
``(E) A description of the steps the Director and the head
of each National Drug Control Program Agency will take to
effectuate the plan.
``(F) Any other relevant information as determined by the
Director.
``(2) Consultation.--In developing the plan required under
paragraph (1), the Director shall consult with the following:
``(A) The public.
``(B) Any evaluation or analysis units and personnel of the
Office.
[[Page H5315]]
``(C) Office officials responsible for implementing privacy
policy.
``(D) Office officials responsible for data governance.
``(E) The appropriate congressional committees.
``(F) Any other individual or entity as determined by the
Director.
``(c) Evidence-based Policy.--
``(1) Harm reduction programs.--When developing the
national drug control policy, any policy of the Director,
including policies relating to syringe exchange programs for
intravenous drug users, shall be based on the best available
medical and scientific evidence regarding the effectiveness
of such policy in promoting individual health, preventing the
spread of infectious disease and the impact of such policy on
drug addiction and use. In making any policy relating to harm
reduction programs, the Director shall consult with the
National Institutes of Health and the National Academy of
Sciences.
``(2) Fund restriction for the legalization of controlled
substances.--The Director shall ensure that no Federal funds
appropriated to the Office shall be expended for any study or
contract relating to the legalization (for a medical use or
any other use) for which a listing in schedule I is in effect
under section 202 of the Controlled Substances Act (21 U.S.C.
812).
``(d) Drug Control Data Dashboard.--
``(1) Establishment.--The Director, in consultation with
the Center Director, shall establish and maintain a data
dashboard on the online portal of the Office to be known as
the `Drug Control Data Dashboard'. The Director shall ensure
the user interface of the dashboard is constructed with
modern design standards. To the extent practicable, the data
made available on the dashboard shall be publicly available
in a machine-readable format and searchable by year, agency,
drug, and location.
``(2) Data.--The data included in the Drug Control Data
Dashboard shall be updated quarterly to the extent
practicable, but not less frequently than annually and shall
include, at a minimum, the following:
``(A) For each substance identified under section
1005(c)(1)(A)(i)--
``(i) the total amount seized and disrupted in the calendar
year and each of the previous 3 calendar years, including to
the extent practicable the amount seized by State, local, and
Tribal governments;
``(ii) the known and estimated flows into the United States
from all sources in the calendar year and each of the
previous 3 calendar years;
``(iii) the total amount of known flows that could not be
interdicted or disrupted in the calendar year and each of the
previous 3 calendar years;
``(iv) the known and estimated levels of domestic
production in the calendar year and each of the previous
three calendar years, including the levels of domestic
production if the drug is a prescription drug, as determined
under the Federal Food, Drug, and Cosmetic Act, for which a
listing is in effect under section 202 of the Controlled
Substances Act (21 U.S.C. 812);
``(v) the average street price for the calendar year and
the highest known street price during the preceding 10-year
period; and
``(vi) to the extent practicable, related prosecutions by
State, local, and Tribal governments.
``(B) For the calendar year and each of the previous three
years data sufficient to show, disaggregated by State and, to
the extent feasible, by region within a State, county, or
city, the following:
``(i) The number of fatal and non-fatal overdoses caused by
each drug identified under subparagraph (A)(i).
``(ii) The prevalence of substance use disorders.
``(iii) The number of individuals who have received
substance use disorder treatment, including medication
assisted treatment, for a substance use disorder, including
treatment provided through publicly-financed health care
programs.
``(iv) The extent of the unmet need for substance use
disorder treatment, including the unmet need for medication-
assisted treatment.
``(C) Data sufficient to show the extent of prescription
drug diversion, trafficking, and misuse in the calendar year
and each of the previous 3 calendar years.
``(D) Any quantifiable measures the Director determines to
be appropriate to detail progress toward the achievement of
the goals of the National Drug Control Strategy.
``(e) Access to Information.--
``(1) In general.--Upon the request of the Director, the
head of any National Drug Control Program Agency shall
cooperate with and provide to the Director any statistics,
studies, reports, and other information prepared or collected
by the agency concerning the responsibilities of the agency
under the National Drug Control Strategy that relate to--
``(A) drug control; or
``(B) the manner in which amounts made available to that
agency for drug control are being used by that agency.
``(2) Protection of intelligence information.--
``(A) In general.--The authorities conferred on the Office
and the Director by this chapter shall be exercised in a
manner consistent with provisions of the National Security
Act of 1947 (50 U.S.C. 401 et seq.). The Director of National
Intelligence shall prescribe such regulations as may be
necessary to protect information provided pursuant to this
chapter regarding intelligence sources and methods.
``(B) Duties of director.--The Director of National
Intelligence and the Director of the Central Intelligence
Agency shall, to the maximum extent practicable in accordance
with subparagraph (A), render full assistance and support to
the Office and the Director.
``(3) Required reports from national drug control program
agencies.--The head of each National Drug Control Program
Agency shall submit to the Director such information and
reports as requested from such National Drug Control Program
Agency by the Director, which shall include from the
appropriate National Drug Control Program Agencies:
``(A) Not later than July 1 of each year, the head of a
National Drug Control Program Agency designated by the
Director shall submit to the Director and the appropriate
congressional committees an assessment of the quantity of
illegal drug cultivation and manufacturing in the United
States on lands owned or under the jurisdiction of their
respective agencies that was seized or eradicated by their
personnel during the preceding calendar year.
``(B) Not later than July 1 of each year, the head of a
designated National Drug Control Program Agency shall submit
to the Director and the appropriate congressional committees
information for the preceding year regarding--
``(i) the number and type of seizures of drugs by each
component of the agency seizing drugs, as well as statistical
information on the geographic areas of such seizures; and
``(ii) the number of air and maritime patrol hours
primarily dedicated to drug supply reduction missions
undertaken by each component of the agency.
``(C) Not later than July 1 of each year, the head of a
designated National Drug Control Program Agency shall submit
to the Director and the appropriate congressional committees
information for the preceding year regarding the number of
air and maritime patrol hours primarily dedicated to drug
supply reduction missions undertaken by each component of the
agency.
``(D) Not later than July 1 of each year, the head of a
designated National Drug Control Program Agency shall submit
to the Director and the appropriate congressional committees
information for the preceding year regarding the number and
type of--
``(i) arrests for drug violations;
``(ii) prosecutions by United States Attorneys for drug
violations; and
``(iii) seizures of drugs by each component of the
Department of Justice seizing drugs, as well as statistical
information on the geographic areas of such seizures.
``(f) Data Exchange Standards for Improved
Interoperability.--
``(1) Interagency and intergovernmental designation and use
of data exchange standards working group.--The Director shall
establish a working group of National Drug Control Program
Agencies, State, local and Tribal government health and law
enforcement agencies, and data governance experts to develop
consensus data exchange standards for necessary categories of
information that allow effective electronic exchange of
information between States, between State agencies, between
States and National Drug Control Program Agencies, and any
other drug control relevant data exchange.
``(2) Data exchange standards must be nonproprietary and
interoperable.--The data exchange standards developed under
paragraph (1) shall, to the extent practicable, be
nonproprietary and interoperable.
``(3) Other requirements.--In developing data exchange
standards under this subsection, the working group shall, to
the extent practicable, incorporate--
``(A) interoperable standards developed and maintained by
an international voluntary consensus standards body, as
defined by the Office of Management and Budget;
``(B) interoperable standards developed and maintained by
intergovernmental partnerships; and
``(C) interoperable standards developed and maintained by
Federal entities with authority over contracting and
financial assistance.
``(4) Data exchange standards for federal reporting.--
``(A) Designation.--The Director may, in consultation with
the working group established under this subsection, National
Drug Control Program Agencies, and State, local, and Tribal
governments, designate data exchange standards to govern
Federal reporting and exchange requirements for National Drug
Control Programs, as appropriate.
``(B) Requirements.--The data exchange reporting standards
designated under subparagraph (A) shall, to the extent
practicable--
``(i) incorporate a widely accepted, nonproprietary,
searchable, machine-readable format;
``(ii) be consistent with and implement applicable
accounting principles;
``(iii) be implemented in a manner that is cost-effective
and improves program efficiency and effectiveness; and
``(iv) be capable of being continually upgraded as
necessary.
``(C) Incorporation of nonproprietary standards.--In
designating data exchange standards under this paragraph, the
Director
[[Page H5316]]
shall, to the extent practicable, incorporate existing
nonproprietary standards.
``(D) Rule of construction.--Nothing in this paragraph
shall be construed to require a change to existing data
exchange standards for Federal reporting about a program
referred to in this section, if the head of the agency
responsible for administering the program finds the standards
to be effective and efficient.
``(5) Termination.--The working group established under
paragraph (1) shall terminate not earlier than 60 days after
the public notification of termination by the Director.
``(g) Annual Data Collection and Dissemination
Requirements.--
``(1) In general.--The Director shall collect and
disseminate, as appropriate, such information as the Director
determines is appropriate, but not less than the information
described in this subsection. To the extent practicable, the
data shall be publicly available in a machine-readable format
on the Drug Control Data Dashboard, be searchable by year,
agency, drug, and location, and cover not less than the
previous 10-year period.
``(2) Preparation and dissemination of information.--The
Director shall prepare and disseminate the following:
``(A) An assessment of current illicit drug use (including
inhalants and steroids) and availability, impact of illicit
drug use, and treatment availability, which assessment shall
include--
``(i) estimates of drug prevalence and frequency of use as
measured by national, State, and local surveys of illicit
drug use and by other special studies of nondependent and
dependent illicit drug use;
``(ii) illicit drug use in the workplace and the
productivity lost by such use; and
``(iii) illicit drug use by arrestees, probationers, and
parolees.
``(B) An assessment of the reduction of illicit drug
availability, for each drug identified under section
1005(c)(1)(A)(i), as measured by--
``(i) the quantities of such drug available for consumption
in the United States;
``(ii) the amount of such drug entering the United States;
``(iii) the number of illicit drug manufacturing
laboratories seized and destroyed of each such drug and the
number of hectares cultivated and destroyed domestically and
in other countries of such drug;
``(iv) the number of metric tons of such drug seized; and
``(v) changes in the price and purity of such drug.
``(C) An assessment of the reduction of the consequences of
illicit drug use and availability, which shall include--
``(i) the cost of treating substance use disorder in the
United States, such as the quantity of illicit drug-related
services provided;
``(ii) the annual national health care cost of illicit drug
use; and
``(iii) the extent of illicit drug-related crime and
criminal activity.
``(D) A determination of the status of substance use
disorder treatment in the United States, by assessing--
``(i) public and private treatment utilization; and
``(ii) the number of illicit drug users the Director
estimates meet diagnostic criteria for treatment.
``Sec. 1014. Authorization of appropriations
``There are authorized to be appropriated to carry out this
chapter, except as otherwise specified, to remain available
until expended, $18,400,000 for each of fiscal years 2019
through 2023.
``SUBCHAPTER II--DRUG-FREE COMMUNITIES SUPPORT PROGRAM
``Sec. 1021. Establishment of drug-free communities support
program
``(a) Establishment.--The Director shall establish a
program to support communities in the development and
implementation of comprehensive, long-term plans and programs
to prevent and treat substance use and misuse among youth.
``(b) Program.--In carrying out the Program, the Director
shall--
``(1) make and track grants to grant recipients;
``(2) provide for technical assistance and training, data
collection, and dissemination of information on state-of-the-
art practices that the Director determines to be effective in
reducing substance use; and
``(3) provide for the general administration of the
Program.
``(c) Administration.--The Director shall appoint an
Administrator to carry out the Program.
``(d) Contracting.--The Director may employ any necessary
staff and may enter into contracts or agreements with
National Drug Control Program Agencies, including interagency
agreements, to delegate authority for the execution of grants
and for such other activities necessary to carry out this
chapter.
``Sec. 1022. Program authorization
``(a) Grant Eligibility.--To be eligible to receive an
initial grant or a renewal grant under this subchapter, a
coalition shall meet each of the following criteria:
``(1) Application.--The coalition shall submit an
application to the Administrator in accordance with section
1023(a)(2).
``(2) Major sector involvement.--
``(A) In general.--The coalition shall consist of 1 or more
representatives of each of the following categories:
``(i) Youth.
``(ii) Parents.
``(iii) Businesses.
``(iv) The media.
``(v) Schools.
``(vi) Organizations serving youth.
``(vii) Law enforcement.
``(viii) Religious or fraternal organizations.
``(ix) Civic and volunteer groups.
``(x) Health care professionals.
``(xi) State, local, or Tribal governmental agencies with
expertise in the field of substance use prevention or
substance use disorders (including, if applicable, the State
authority with primary authority for substance use and
misuse).
``(xii) Other organizations involved in reducing the
prevalence of substance use and misuse or substance use
disorders.
``(B) Elected officials.--If feasible, in addition to
representatives from the categories listed in subparagraph
(A), the coalition shall have an elected official (or a
representative of an elected official) from--
``(i) the Federal Government; and
``(ii) the government of the appropriate State and
political subdivision thereof or the governing body or an
Indian tribe (as that term is defined in section 4(e) of the
Indian Self-Determination Act (25 U.S.C. 5304)).
``(C) Representation.--An individual who is a member of the
coalition may serve on the coalition as a representative of
not more than 1 category listed under subparagraph (A).
``(3) Commitment.--The coalition shall demonstrate, to the
satisfaction of the Administrator--
``(A) that the representatives of the coalition have worked
together on substance use and misuse reduction initiatives,
which, at a minimum, includes initiatives that target drugs
described in section 1027(6)(A), for a period of not less
than 6 months, acting through entities such as task forces,
subcommittees, or community boards; and
``(B) substantial participation from volunteer leaders in
the community involved (especially in cooperation with
individuals involved with youth such as parents, teachers,
coaches, youth workers, and members of the clergy).
``(4) Mission and strategies.--The coalition shall, with
respect to the community involved--
``(A) have as its principal mission the reduction of
illegal drug use, which, at a minimum, includes the use of
illegal drugs described in section 1027(6)(A), in a
comprehensive and long-term manner, with a primary focus on
youth in the community;
``(B) describe and document the nature and extent of the
substance use and misuse problem, which, at a minimum,
includes the use and misuse of drugs described in section
1027(6)(A), in the community;
``(C)(i) provide a description of substance use and misuse
prevention and treatment programs and activities, which, at a
minimum, includes programs and activities relating to the use
and misuse of drugs described in section 1027(6)(A), in
existence at the time of the grant application; and
``(ii) identify substance use and misuse programs and
service gaps, which, at a minimum, includes programs and gaps
relating to the use and misuse of drugs described in section
1027(6)(A), in the community;
``(D) develop a strategic plan to reduce substance use and
misuse among youth, which, at a minimum, includes the use and
misuse of drugs described in section 1027(6)(A), in a
comprehensive and long-term fashion; and
``(E) work to develop a consensus regarding the priorities
of the community to combat substance use and misuse among
youth, which, at a minimum, includes the use and misuse of
drugs described in section 1027(6)(A).
``(5) Sustainability.--The coalition shall demonstrate that
the coalition is an ongoing concern by demonstrating that the
coalition--
``(A) is--
``(i)(I) a nonprofit organization; or
``(II) an entity that the Administrator determines to be
appropriate; or
``(ii) part of, or is associated with, an established legal
entity;
``(B) receives financial support (including, in the
discretion of the Administrator, in-kind contributions) from
non-Federal sources; and
``(C) has a strategy to solicit substantial financial
support from non-Federal sources to ensure that the coalition
and the programs operated by the coalition are self-
sustaining.
``(6) Accountability.--The coalition shall--
``(A) establish a system to measure and report outcomes--
``(i) consistent with common indicators and evaluation
protocols established by the Administrator; and
``(ii) approved by the Administrator;
``(B) conduct--
``(i) for an initial grant under this subchapter, an
initial benchmark survey of drug use among youth (or use
local surveys or performance measures available or accessible
in the community at the time of the grant application); and
``(ii) biennial surveys (or incorporate local surveys in
existence at the time of the evaluation) to measure the
progress and effectiveness of the coalition; and
``(C) provide assurances that the entity conducting an
evaluation under this paragraph, or from which the coalition
receives information, has experience--
[[Page H5317]]
``(i) in gathering data related to substance use and misuse
among youth; or
``(ii) in evaluating the effectiveness of community anti-
drug coalitions.
``(7) Additional criteria.--The Director shall not impose
any eligibility criteria on new applicants or renewal
grantees not provided in this chapter.
``(b) Grant Amounts.--
``(1) In general.--
``(A) Grants.--
``(i) In general.--Subject to clause (iv), for a fiscal
year, the Administrator may grant to an eligible coalition
under this paragraph, an amount not to exceed the amount of
non-Federal funds raised by the coalition, including in-kind
contributions, for that fiscal year.
``(ii) Suspension of grants.--If such grant recipient fails
to continue to meet the criteria specified in subsection (a),
the Administrator may suspend the grant, after providing
written notice to the grant recipient and an opportunity to
appeal.
``(iii) Renewal grants.--Subject to clause (iv), the
Administrator may award a renewal grant to a grant recipient
under this subparagraph for each fiscal year following the
fiscal year for which an initial grant is awarded, in an
amount not to exceed the amount of non-Federal funds raised
by the coalition, including in-kind contributions, for that
fiscal year, during the 4-year period following the period of
the initial grant.
``(iv) Limitation.--The amount of a grant award under this
subparagraph may not exceed $125,000 for a fiscal year.
``(B) Coalition awards.--
``(i) In general.--Except as provided in clause (ii), the
Administrator may, with respect to a community, make a grant
to 1 eligible coalition that represents that community.
``(ii) Exception.--The Administrator may make a grant to
more than 1 eligible coalition that represents a community
if--
``(I) the eligible coalitions demonstrate that the
coalitions are collaborating with one another; and
``(II) each of the coalitions has independently met the
requirements set forth in subsection (a).
``(2) Rural coalition grants.--
``(A) In general.--
``(i) In general.--In addition to awarding grants under
paragraph (1), to stimulate the development of coalitions in
sparsely populated and rural areas, the Administrator may
award a grant in accordance with this section to a coalition
that represents a county with a population that does not
exceed 30,000 individuals. In awarding a grant under this
paragraph, the Administrator may waive any requirement under
subsection (a) if the Administrator considers that waiver to
be appropriate.
``(ii) Matching requirement.--Subject to subparagraph (C),
for a fiscal year, the Administrator may grant to an eligible
coalition under this paragraph, an amount not to exceed the
amount of non-Federal funds raised by the coalition,
including in-kind contributions, for that fiscal year.
``(iii) Suspension of grants.--If such grant recipient
fails to continue to meet any criteria specified in
subsection (a) that has not been waived by the Administrator
pursuant to clause (i), the Administrator may suspend the
grant, after providing written notice to the grant recipient
and an opportunity to appeal.
``(B) Renewal grants.--The Administrator may award a
renewal grant to an eligible coalition that is a grant
recipient under this paragraph for each fiscal year following
the fiscal year for which an initial grant is awarded, in an
amount not to exceed the amount of non-Federal funds raised
by the coalition, including in-kind contributions, during the
4-year period following the period of the initial grant.
``(C) Limitations.--
``(i) Amount.--The amount of a grant award under this
paragraph shall not exceed $125,000 for a fiscal year.
``(ii) Awards.--With respect to a county referred to in
subparagraph (A), the Administrator may award a grant under
this section to not more than 1 eligible coalition that
represents the county.
``(3) Additional grants.--
``(A) In general.--Subject to subparagraph (F), the
Administrator may award an additional grant under this
paragraph to an eligible coalition awarded a grant under
paragraph (1) or (2) for any first fiscal year after the end
of the 4-year period following the period of the initial
grant under paragraph (1) or (2), as the case may be.
``(B) Scope of grants.--A coalition awarded a grant under
paragraph (1) or (2), including a renewal grant under such
paragraph, may not be awarded another grant under such
paragraph, and is eligible for an additional grant under this
section only under this paragraph.
``(C) No priority for applications.--The Administrator may
not afford a higher priority in the award of an additional
grant under this paragraph than the Administrator would
afford the applicant for the grant if the applicant were
submitting an application for an initial grant under
paragraph (1) or (2) rather than an application for a grant
under this paragraph.
``(D) Renewal grants.--Subject to subparagraph (F), the
Administrator may award a renewal grant to a grant recipient
under this paragraph for each of the fiscal years of the 4-
fiscal-year period following the fiscal year for which the
initial additional grant under subparagraph (A) is awarded in
an amount not to exceed amounts as follows:
``(i) For the first and second fiscal years of that 4-
fiscal-year period, the amount of the non-Federal funds,
including in-kind contributions, raised by the coalition for
the applicable fiscal year is not less than 125 percent of
the amount awarded.
``(ii) For the third and fourth fiscal years of that 4-
fiscal-year period, the amount of the non-Federal funds,
including in-kind contributions, raised by the coalition for
the applicable fiscal year is not less than 150 percent of
the amount awarded.
``(E) Suspension.--If a grant recipient under this
paragraph fails to continue to meet the criteria specified in
subsection (a), the Administrator may suspend the grant,
after providing written notice to the grant recipient and an
opportunity to appeal.
``(F) Limitation.--The amount of a grant award under this
paragraph may not exceed $125,000 for a fiscal year.
``(4) Process for suspension.--A grantee shall not be
suspended or terminated under paragraph (1)(A)(ii),
(2)(A)(iii), or (3)(E) unless that grantee is afforded a
fair, timely, and independent appeal prior to such suspension
or termination.
``(c) Treatment of Funds for Coalitions Representing
Certain Organizations.--Funds appropriated for the substance
use and misuse activities of a coalition that includes a
representative of the Bureau of Indian Affairs, the Indian
Health Service, or a Tribal government agency with expertise
in the field of substance use prevention may be counted as
non-Federal funds raised by the coalition for purposes of
this section.
``(d) Priority in Awarding Grants.--In awarding grants
under subsection (b)(1)(A)(i), priority shall be given to a
coalition serving economically disadvantaged areas.
``Sec. 1023. Information collection and dissemination with
respect to grant recipients
``(a) Coalition Information.--
``(1) General auditing authority.--For the purpose of audit
and examination, the Administrator--
``(A) shall have access to any books, documents, papers,
and records that are pertinent to any grant or grant renewal
request under this subchapter; and
``(B) may periodically request information from a grant
recipient to ensure that the grant recipient meets the
applicable criteria under section 1022(a).
``(2) Application process.--The Administrator shall issue a
request for proposal regarding, with respect to the grants
awarded under section 1022, the application process, grant
renewal, and suspension or withholding of renewal grants.
Each application under this paragraph shall be in writing and
shall be subject to review by the Administrator.
``(3) Reporting.--The Administrator shall, to the maximum
extent practicable and in a manner consistent with applicable
law, minimize reporting requirements by a grant recipient and
expedite any application for a renewal grant made under this
subchapter.
``(b) Data Collection and Dissemination.--
``(1) In general.--The Administrator may collect data
from--
``(A) national substance use and misuse organizations that
work with eligible coalitions, community anti-drug
coalitions, departments or agencies of the Federal
Government, or State or local governments and the governing
bodies of Indian Tribes; and
``(B) any other entity or organization that carries out
activities that relate to the purposes of the Program.
``(2) Activities of administrator.--The Administrator may--
``(A) evaluate the utility of specific initiatives relating
to the purposes of the Program;
``(B) conduct an evaluation of the Program; and
``(C) disseminate information described in this subsection
to--
``(i) eligible coalitions and other substance use
prevention organizations; and
``(ii) the general public.
``(3) Consultation.--The Administrator shall carry out
activities under this subsection in consultation with the
National Community Antidrug Coalition Institute.
``(4) Limitation on use of certain funds for evaluation of
program.--Amounts for activities under paragraph (2)(B) may
not be derived from amounts under section 1028(a) except for
amounts that are available under section 1028(b) for
administrative costs.
``Sec. 1024. Technical assistance and training
``(a) In General.--
``(1) Technical assistance and agreements.--With respect to
any grant recipient or other organization, the Administrator
may--
``(A) offer technical assistance and training; and
``(B) enter into contracts and cooperative agreements.
``(2) Coordination of programs.--The Administrator may
facilitate the coordination of programs between a grant
recipient and other organizations and entities.
``(b) Training.--The Administrator may provide training to
any representative designated by a grant recipient in--
``(1) coalition building;
``(2) task force development;
``(3) mediation and facilitation, direct service,
assessment and evaluation; or
``(4) any other activity related to the purposes of the
Program.
[[Page H5318]]
``Sec. 1025. Supplemental grants for coalition mentoring
activities
``(a) Authority to Make Grants.--As part of the Program,
the Director may award an initial grant under this
subsection, and renewal grants under subsection (f), to any
coalition awarded a grant under section 1022 that meets the
criteria specified in subsection (d) in order to fund
coalition mentoring activities by such coalition in support
of the program.
``(b) Treatment With Other Grants.--
``(1) Supplement.--A grant awarded to a coalition under
this section is in addition to any grant awarded to the
coalition under section 1022.
``(2) Requirement for basic grant.--A coalition may not be
awarded a grant under this section for a fiscal year unless
the coalition was awarded a grant or renewal grant under
section 1022(b) for that fiscal year.
``(c) Application.--A coalition seeking a grant under this
section shall submit to the Administrator an application for
the grant in such form and manner as the Administrator may
require.
``(d) Criteria.--A coalition meets the criteria specified
in this subsection if the coalition--
``(1) has been in existence for at least 5 years;
``(2) has achieved, by or through its own efforts,
measurable results in the prevention and treatment of
substance use and misuse among youth;
``(3) has staff or members willing to serve as mentors for
persons seeking to start or expand the activities of other
coalitions in the prevention and treatment of substance use
and misuse;
``(4) has demonstrable support from some members of the
community in which the coalition mentoring activities to be
supported by the grant under this section are to be carried
out; and
``(5) submits to the Administrator a detailed plan for the
coalition mentoring activities to be supported by the grant
under this section.
``(e) Use of Grant Funds.--A coalition awarded a grant
under this section shall use the grant amount for mentoring
activities to support and encourage the development of new,
self-supporting community coalitions that are focused on the
prevention and treatment of substance use and misuse in such
new coalitions' communities. The mentoring coalition shall
encourage such development in accordance with the plan
submitted by the mentoring coalition under subsection (d)(5).
``(f) Renewal Grants.--The Administrator may make a renewal
grant to any coalition awarded a grant under subsection (a),
or a previous renewal grant under this subsection, if the
coalition, at the time of application for such renewal
grant--
``(1) continues to meet the criteria specified in
subsection (d); and
``(2) has made demonstrable progress in the development of
one or more new, self-supporting community coalitions that
are focused on the prevention and treatment of substance use
and misuse.
``(g) Grant Amounts.--
``(1) In general.--Subject to paragraphs (2) and (3), the
total amount of grants awarded to a coalition under this
section for a fiscal year may not exceed the amount of non-
Federal funds raised by the coalition, including in-kind
contributions, for that fiscal year. Funds appropriated for
the substance use and misuse activities of a coalition that
includes a representative of the Bureau of Indian Affairs,
the Indian Health Service, or a Tribal government agency with
expertise in the field of substance use prevention may be
counted as non-Federal funds raised by the coalition.
``(2) Initial grants.--The amount of the initial grant
awarded to a coalition under subsection (a) may not exceed
$75,000.
``(3) Renewal grants.--The total amount of renewal grants
awarded to a coalition under subsection (f) for any fiscal
year may not exceed $75,000.
``(h) Fiscal Year Limitation on Amount Available for
Grants.--The total amount available for grants under this
section, including renewal grants under subsection (f), in
any fiscal year may not exceed the amount equal to five
percent of the amount authorized to be appropriated by
section 1028 for that fiscal year.
``(i) Priority in Awarding Initial Grants.--In awarding
initial grants under this section, priority shall be given to
a coalition that expressly proposes to provide mentorship to
a coalition or aspiring coalition serving economically
disadvantaged areas.
``Sec. 1026. Authorization for National Community Antidrug
Coalition Institute
``(a) In General.--The Director shall, using amounts
authorized to be appropriated by subsection (d), make a
competitive grant to provide for the continuation of the
National Community Anti-drug Coalition Institute.
``(b) Eligible Organizations.--An organization eligible for
the grant under subsection (a) is any national nonprofit
organization that represents, provides technical assistance
and training to, and has special expertise and broad,
national-level experience in community antidrug coalitions
under this subchapter.
``(c) Use of Grant Amount.--The organization that receives
the grant under subsection (a) shall continue a National
Community Anti-Drug Coalition Institute to--
``(1) provide education, training, and technical assistance
for coalition leaders and community teams, with emphasis on
the development of coalitions serving economically
disadvantaged areas;
``(2) develop and disseminate evaluation tools, mechanisms,
and measures to better assess and document coalition
performance measures and outcomes; and
``(3) bridge the gap between research and practice by
translating knowledge from research into practical
information.
``(d) Authorization of Appropriations.--The Director shall,
using amounts authorized to be appropriated by section 1028,
make a grant of $2,000,000 under subsection (a), for each of
the fiscal years 2019 through 2023.
``Sec. 1027. Definitions
``In this subchapter:
``(1) Administrator.--The term `Administrator' means the
Administrator appointed by the Director under section
1021(c).
``(2) Community.--The term `community' shall have the
meaning provided that term by the Administrator.
``(3) Eligible coalition.--The term `eligible coalition'
means a coalition that meets the applicable criteria under
section 1022(a).
``(4) Grant recipient.--The term `grant recipient' means
the recipient of a grant award under section 1022.
``(5) Program.--The term `Program' means the program
established under section 1021(a).
``(6) Substance use and misuse.--The term `substance use
and misuse' means--
``(A) the illegal use or misuse of drugs, including
substances for which a listing is in effect under any of
schedules I through V under section 202 of the Controlled
Substances Act (21 U.S.C. 812);
``(B) the misuse of inhalants or over the counter drugs; or
``(C) the use of alcohol, tobacco, or other related product
as such use is prohibited by State or local law.
``(7) Youth.--The term `youth' shall have the meaning
provided that term by the Administrator.
``Sec. 1028. Drug-free communities reauthorization
``(a) Authorization of Appropriations.--There are
authorized to be appropriated to the Office to carry out this
subchapter $99,000,000 for each of the fiscal years 2019
through 2023.
``(b) Administrative Costs.--Not more than 8 percent of the
funds appropriated for this subchapter may be used by the
Office or, in the discretion of the Director, an agency
delegated to carry out the program under section 1021(d) to
pay for administrative costs associated with carrying out the
program.''.
(d) Technical and Conforming Amendment.--The table of
chapters for subtitle I of title 31, United States Code, is
amended by adding at the end the following new item:
``10. Office of National Drug Control.......................1001''.....
SEC. 3. HIGH INTENSITY DRUG TRAFFICKING AREAS PROGRAM.
(a) Establishment.--
(1) In general.--There is established in the Office a
program to be known as the High Intensity Drug Trafficking
Areas Program (in this section referred to as the
``Program'').
(2) Purpose.--The purpose of the Program is to reduce drug
trafficking and drug production in the United States by--
(A) facilitating cooperation among Federal, State, local,
and Tribal law enforcement agencies to share information and
implement coordinated enforcement activities;
(B) enhancing law enforcement intelligence sharing among
Federal, State, local, and Tribal law enforcement agencies;
(C) providing reliable law enforcement intelligence to law
enforcement agencies needed to design effective enforcement
strategies and operations; and
(D) supporting coordinated law enforcement strategies which
maximize use of available resources to reduce the supply of
illegal drugs in designated areas and in the United States as
a whole.
(b) Designation.--
(1) In general.--The Director, in consultation with the
Attorney General, the Secretary of the Treasury, the
Secretary of Homeland Security, the head of each National
Drug Control Program Agency, and the Governor of each
applicable State, may designate any specified area of the
United States as a high intensity drug trafficking area.
(2) Activities.--After making a designation under paragraph
(1) and in order to provide Federal assistance to the area so
designated, the Director may--
(A) obligate such sums as are appropriated for the Program;
(B) direct the temporary reassignment of Federal personnel
to such area, subject to the approval of the head of the
agency that employs such personnel;
(C) take any other action authorized under this section or
chapter 10 of title 31, United States Code, as added by
section 2(c), to provide increased Federal assistance to
those areas; and
(D) coordinate activities under this section (specifically
administrative, recordkeeping, and funds management
activities) with State, local, and Tribal officials.
(c) Petitions for Designation.--The Director shall
establish and maintain regulations under which a coalition of
interested law enforcement agencies from an area may petition
for designation as a high intensity drug trafficking area (in
this section referred
[[Page H5319]]
to as the ``HIDTA''). Such regulations shall provide for a
regular review by the Director of the petition, including a
recommendation regarding the merit of the petition to the
Director by a panel of qualified, independent experts.
(d) Factors for Consideration.--In considering whether to
designate an area under this section as a high intensity drug
trafficking area, the Director shall consider, in addition to
such other criteria as the Director considers to be
appropriate, the extent to which--
(1) the area is a significant center of illegal drug
production, manufacturing, importation, or distribution;
(2) State, local, and Tribal law enforcement agencies have
committed resources to respond to the drug trafficking
problem in the area, thereby indicating a determination to
respond aggressively to the problem;
(3) drug-related activities in the area are having a
significant harmful impact in the area, and in other areas of
the country; and
(4) a significant increase in allocation of Federal
resources is necessary to respond adequately to drug-related
activities in the area.
(e) Organization of High Intensity Drug Trafficking
Areas.--
(1) Executive board and officers.--To be eligible for funds
appropriated under this section, each high intensity drug
trafficking area shall be governed by an Executive Board. The
Executive Board shall designate a chairman, vice chairman,
and any other officers to the Executive Board that it
determines are necessary.
(2) Responsibilities.--The Executive Board of a high
intensity drug trafficking area shall be responsible for--
(A) providing direction and oversight in establishing and
achieving the goals of the high intensity drug trafficking
area;
(B) managing the funds of the high intensity drug
trafficking area;
(C) reviewing and approving all funding proposals
consistent with the overall objective of the high intensity
drug trafficking area; and
(D) reviewing and approving all reports to the Director on
the activities of the high intensity drug trafficking area.
(3) Board representation.--None of the funds appropriated
under this section may be expended for any high intensity
drug trafficking area, or for a partnership or region of a
high intensity drug trafficking area, if the Executive Board
for such area, region, or partnership, does not apportion an
equal number of votes between representatives of
participating agencies and representatives of participating
State, local, and Tribal agencies. Where it is impractical
for an equal number of representatives of agencies and State,
local, and Tribal agencies to attend a meeting of an
Executive Board in person, the Executive Board may use a
system of proxy votes or weighted votes to achieve the voting
balance required by this paragraph.
(4) No agency relationship.--The eligibility requirements
of this section are intended to ensure the responsible use of
Federal funds. Nothing in this section is intended to create
an agency relationship between individual high intensity drug
trafficking areas and the Federal Government.
(f) Use of Funds.--The Director shall ensure that not more
than 5 percent of Federal funds appropriated for the Program
are expended for substance use disorder treatment programs
and not more than 5 percent of the Federal funds appropriated
for the Program are expended for drug prevention programs.
(g) Counterterrorism Activities.--
(1) Assistance authorized.--The Director may authorize use
of resources available for the Program to assist Federal,
State, local, and Tribal law enforcement agencies in
investigations and activities related to terrorism and
prevention of terrorism, especially but not exclusively with
respect to such investigations and activities that are also
related to drug trafficking.
(2) Limitation.--The Director shall ensure--
(A) that assistance provided under paragraph (1) remains
incidental to the purpose of the Program to reduce drug
availability and carry out drug-related law enforcement
activities; and
(B) that significant resources of the Program are not
redirected to activities exclusively related to terrorism,
except on a temporary basis under extraordinary
circumstances, as determined by the Director.
(h) Role of Drug Enforcement Administration.--The Director,
in consultation with the Attorney General, shall ensure that
a representative of the Drug Enforcement Administration is
included in the Intelligence Support Center for each high
intensity drug trafficking area.
(i) Emerging Threat Response Fund.--
(1) In general.--Subject to the availability of
appropriations, the Director may expend up to 10 percent of
the amounts appropriated under this section on a
discretionary basis, in accordance with the criteria
established under paragraph (2)--
(A) to respond to any emerging drug trafficking threat in
an existing high intensity drug trafficking area;
(B) to establish a new high intensity drug trafficking
area; or
(C) to expand an existing high intensity drug trafficking
area.
(2) Consideration of impact.--In allocating funds under
this subsection, the Director shall consider--
(A) the impact of activities funded on reducing overall
drug traffic in the United States, or minimizing the
probability that an emerging drug trafficking threat will
spread to other areas of the United States; and
(B) such other criteria as the Director considers
appropriate.
(j) Annual Hidta Program Budget Submissions.--As part of
the documentation that supports the President's annual budget
request for the Office, the Director shall submit to Congress
a budget justification that includes--
(1) the amount proposed for each HIDTA, conditional upon a
review by the Office of the request submitted by such HIDTA
and the performance of such HIDTA, with supporting narrative
descriptions and rationale for each request;
(2) a detailed justification that explains--
(A) the reasons for the proposed funding level and how such
funding level was determined based on a current assessment of
the drug trafficking threat in each high intensity drug
trafficking area;
(B) how such funding will ensure that the goals and
objectives of each such area will be achieved; and
(C) how such funding supports the National Drug Control
Strategy; and
(3) the amount of HIDTA funds used to investigate and
prosecute organizations and individuals trafficking in each
major illicit drug, as identified by the Director, in the
prior calendar year, and a description of how those funds
were used.
(k) Hidta Annual Evaluation Report.--As part of each report
submitted pursuant to section 1006(a) of title 31, United
States Code, as added by section 2(c), the Director shall
include, for each designated high intensity drug trafficking
area, a report that--
(1) describes--
(A) the specific purposes for the high intensity drug
trafficking area; and
(B) the specific long-term and short-term goals and
objectives for the high intensity drug trafficking area;
(2) includes an evaluation of the performance of the high
intensity drug trafficking area in accomplishing the specific
long-term and short-term goals and objectives identified
under subparagraph (1)(B);
(3) assesses the number and operation of all federally
funded drug enforcement task forces within such high
intensity drug trafficking area;
(4) describes--
(A) each Federal, State, local, and Tribal drug enforcement
task force operating in such high intensity drug trafficking
area;
(B) how such task forces coordinate with each other, with
any high intensity drug trafficking area task force, and with
investigations receiving funds from the Organized Crime and
Drug Enforcement Task Force;
(C) what steps, if any, each such task force takes to share
information regarding drug trafficking and drug production
with other federally funded drug enforcement task forces in
the high intensity drug trafficking area;
(D) the role of the high intensity drug trafficking area in
coordinating the sharing of such information among task
forces;
(E) the nature and extent of cooperation by each Federal,
State, local, and Tribal participant in ensuring that such
information is shared among law enforcement agencies and with
the high intensity drug trafficking area;
(F) the nature and extent to which information sharing and
enforcement activities are coordinated with joint terrorism
task forces in the high intensity drug trafficking area; and
(G) any recommendations for measures needed to ensure that
task force resources are utilized efficiently and effectively
to reduce the availability of illegal drugs in the high
intensity drug trafficking areas; and
(5) in consultation with the Director of National
Intelligence--
(A) evaluates existing and planned law enforcement
intelligence systems supported by such high intensity drug
trafficking area, or utilized by task forces receiving any
funding under the Program, including the extent to which such
systems ensure access and availability of law enforcement
intelligence to Federal, State, local, and Tribal law
enforcement agencies within the high intensity drug
trafficking area and outside of such area;
(B) evaluates the extent to which Federal, State, local,
and Tribal law enforcement agencies participating in each
high intensity drug trafficking area are sharing law
enforcement intelligence information to assess current drug
trafficking threats and design appropriate enforcement
strategies; and
(C) identifies the measures needed to improve effective
sharing of information and law enforcement intelligence
regarding drug trafficking and drug production among Federal,
State, local, and Tribal law enforcement participating in a
high intensity drug trafficking area, and between such
agencies and similar agencies outside the high intensity drug
trafficking area.
(l) Coordination of Law Enforcement Intelligence Sharing
With Organized Crime Drug Enforcement Task Force Program.--
(1) Drug enforcement intelligence sharing.--The Director,
in consultation with the Attorney General, shall ensure that
any drug enforcement intelligence obtained by the
Intelligence Support Center for each high intensity drug
trafficking area is shared, on a timely basis, with the drug
intelligence fusion center operated by the Organized Crime
Drug Enforcement Task Force of the Department of Justice.
[[Page H5320]]
(2) Certification.--Before the Director awards any funds to
a high intensity drug trafficking area, the Director shall
certify that the law enforcement entities participating in
that HIDTA are providing laboratory seizure data to the
national clandestine laboratory database at the El Paso
Intelligence Center.
(m) Authorization of Appropriations.--There is authorized
to be appropriated to the Office to carry out this section
$280,000,000 for each fiscal years 2019 through 2023.
(n) Specific Purposes.--
(1) In general.--The Director shall ensure that, of the
amounts appropriated for a fiscal year for the Program, at
least 2.5 percent is used in high intensity drug trafficking
areas with severe neighborhood safety and illegal drug
distribution problems.
(2) Required uses.--The funds used under paragraph (1)
shall be used to ensure the safety of neighborhoods and the
protection of communities, including the prevention of the
intimidation of witnesses of illegal drug distribution and
related activities and the establishment of or support for
programs that provide protection or assistance to witnesses
in court proceedings.
(3) Best practice models.--The Director shall work with the
HIDTAs to develop and maintain best practice models to assist
State, local, and Tribal governments in addressing witness
safety, relocation, financial and housing assistance, or any
other services related to witness protection or assistance in
cases of illegal drug distribution and related activities.
The Director shall ensure dissemination of the best practice
models to each HIDTA.
SEC. 4. OPIOID CRISIS RESPONSE.
(a) Emerging Threat Designation.--The Director shall
designate opioids and opioid analogues as emerging drug
threats, in accordance with section 1009 of title 31, United
States Code, as added by section 2(c).
(b) Opioid Response Plan.--
(1) Issuance.--Not later than 60 days after the date of the
enactment of this Act, the Director shall publish, make
publicly available, and notify the President and the
appropriate congressional committees of, the plan required
under section 1009 of title 31, United States Code, as added
by section 2(c), to be designated as the ``National Opioid
Crisis Response Plan''.
(2) Contents.--The Director shall ensure the plan
establishes measurable goals, including reducing fatal and
non-fatal overdoses, and includes the following:
(A) An initiative to ensure the United States mail is
effectively screened to prevent illicit drugs from entering
the United States, including--
(i) designating the United States Postal Service as a
National Drug Control Program Agency;
(ii) directing the United States Postal Service and any
other related National Drug Control Program Agency to take
any appropriate actions necessary to reduce the amount of
illicit drugs entering the country; and
(iii) developing an international coordination plan, in
consultation with the National Drug Control Program Agencies
and in accordance with section 1010 of such title 31, United
States Code, as added by section 2(c), to include efforts to
address international drug control initiatives and strengthen
bilateral and multilateral strategies to reduce illicit drugs
and precursor chemicals from entering the United States
through international mail or across land borders or ports of
entry.
(B) Support for universal adoption of evidence-based
prescribing guidelines, including--
(i) establishing a task force to supplement existing
prescribing guidelines with evidence-based standards and to
facilitate, coordinate, and, as appropriate, conduct research
to inform such guidelines;
(ii) encouraging the adoption of evidence-based prescribing
guidelines by each relevant agency, State and local
governments, and private sector organizations;
(iii) issuing guidance to National Drug Control Program
Agencies to, as appropriate, revise regulations to ensure
professionals have effective continuing education
requirements; and
(iv) disseminating and encouraging the adoption of best
practices and evidence-based guidelines for effective
prescribing practices.
(C) A program to monitor the prescription drug market and
illicit drug market for changes in trends relevant to
reducing the supply or demand of such drugs.
(D) An initiative to facilitate and coordinate Federal,
State and local government initiatives, studies, and pilot or
demonstration programs designed to evaluate the benefits of
drug courts and related programs that reduce substance use
prevalence.
(E) A program, developed in coordination with the private
sector, to--
(i) facilitate the development of treatment and abuse-
deterrent products, in accordance with section 1010(c) of
title 31, United States Code, as added by section 2(c); and
(ii) encourage the expansion of medication disposal
programs and technology.
(F) Initiatives to--
(i) encourage the National Drug Control Program Agencies
and the program established under section 1010(d) of title
31, United States Code, as added by section 2(c), to
prioritize the development of sentencing standards or model
codes for trafficking opioids and opioid analogues; and
(ii) to advise States on establishing laws and policies to
address opioid issues based on the recommendations developed
and set forth by the President's Commission on Combating Drug
Addiction and the Opioid Crisis.
(G) A program to identify successful college recovery
programs, including sober housing programs that provide a
shared living residence free of alcohol or illicit drug use
for individuals recovering from drug or alcohol addiction and
substance use disorders, on college campuses and disseminate
best practices to Colleges and Universities to increase the
number and capacity of such programs.
(H) Convening working groups, consisting of the appropriate
National Drug Control Program Agencies, State, local and
Tribal governments, and other appropriate stakeholders,
established in accordance with section 1010 of title 31,
United States Code, as added by section 2(c)--
(i) to support Prescription Drug Monitoring Programs by--
(I) facilitating the sharing and interoperability of
program data among States and Federal prescription drug
monitoring programs;
(II) assisting States in increasing utilization of such
programs;
(III) facilitating efforts to incorporate available
overdose and naloxone deployment data into such programs;
(IV) evaluating barriers to integrating program data with
electronic health records; and
(V) offering recommendations to address identified
barriers; and
(ii) to develop standards, and encourage the use of such
standards, for the collection of data necessary to understand
and monitor the opioid crisis, including--
(I) State medical examiner reports on deaths caused by
overdoses and related statistical data; and
(II) first responder opioid intoxication incidents.
(I) Research initiatives, to be initiated not later than 30
days after the issuance of the plan, to evaluate the uses and
barriers to use of and the effects of improving the following
programs:
(i) Medication Assisted Treatment.
(ii) Data collection systems used to confirm opioid use by
individuals who have been arrested or hospitalized.
(J) A requirement for an Advisory Committee on Substance
Use Disorder Treatment Standards, to be established not later
than 120 days after the issuance of the plan, to promulgate
model evidence-based standards for substance use disorder
treatment and recovery facilities which--
(i) shall be chaired by the Director;
(ii) shall include as members of the advisory committee
representatives of the relevant National Drug Control Program
Agencies;
(iii) may include as members of the advisory committee
government regulators, State representatives, consumer
representatives, substance use disorder treatment providers,
recovery residence owners and operators, and purchasers of
substance use disorder treatments; and
(iv) shall ensure such model standards are promulgated no
later than 2 years after the date of the issuance of the
plan.
(c) Recommendations.--Not later than 1 year after the date
of the enactment of this Act, the Director shall submit to
the appropriate congressional committees a report on the
results of the initiatives conducted under subsection
(b)(2)(I) and may include recommendations based on such
results.
(d) Grant Report to Congress.--Not later than 1 year after
the date of the enactment of this Act, the Director shall
submit to the appropriate congressional committees an
assessment on the feasibility of block grants of Federal
funding to States.
SEC. 5. EXCEPTIONS AND RULES OF CONSTRUCTION.
(a) Inapplicability to Certain Programs.--This Act, and the
amendments made by this Act, shall not apply to the National
Intelligence Program and the Military Intelligence Program,
unless such program or an element of such program is
designated as a National Drug Control Program--
(1) by the President; or
(2) jointly by--
(A) in the case of the National Intelligence Program, the
Director and the Director of National Intelligence; or
(B) in the case of the Military Intelligence Program, the
Director, the Director of National Intelligence, and the
Secretary of Defense.
(b) Classified Information.--Any contents of any report
required under this Act, or the amendments made by this Act,
that involve information properly classified under criteria
established by an Executive order shall be presented to
Congress separately from the rest of such report.
(c) Use of Existing Resources.--To the extent practicable,
the Director and the head of each agency shall use existing
procedures and systems to carry out agency requirements under
this Act, and the amendments made by this Act.
SEC. 6. GAO AUDIT AND REPORTS.
Not later than three and six years after the date of the
enactment of this Act, the Comptroller General shall--
(1) conduct an audit relating to the programs and
operations of--
(A) the Office; and
[[Page H5321]]
(B) certain programs within the Office, including--
(i) the High Intensity Drug Trafficking Areas Program;
(ii) the Drug-Free Communities Program; and
(iii) the campaign under section 1009(d) of title 31, as
added by section 2(c); and
(2) submit to the Director and the appropriate
congressional committees a report containing an evaluation of
and recommendations on the--
(A) policies and activities of the programs and operations
subject to the audit;
(B) economy, efficiency, and effectiveness in the
administration of the reviewed programs and operations; and
(C) policy or management changes needed to prevent and
detect fraud and abuse in such programs and operations.
SEC. 7. REPEALS.
(a) Repeals to the Law.--The following provisions are
repealed:
(1) The Office of National Drug Control Policy
Reauthorization Act of 1998 (Public Law 105-277; 21 U.S.C.
1701 et seq.).
(2) Chapter 2 of the National Narcotics Leadership Act of
1988 (Public Law 100-690; 21 U.S.C. 1501 et seq.).
(3) Section 203 of the Office of National Drug Control
Policy Reauthorization Act of 2006 (Public Law 109-469; 21
U.S.C. 1708a).
(4) Section 1105 of the Office of National Drug Control
Policy Reauthorization Act of 2006 (Public Law 109-469; 21
U.S.C. 1701 note).
(5) Section 1110 of Office of National Drug Control Policy
Reauthorization Act of 2006 (Public Law 109-469; 21 U.S.C.
1705 note).
(6) Section 1110A of the Office of National Drug Control
Policy Reauthorization Act of 2006 (Public Law 109-469; 21
U.S.C. 1705 note).
(7) Section 4 of Public Law 107-82 (21 U.S.C. 1521 note).
(b) Effect on the Code.--The Law Revision Counsel shall
ensure that the website and any other publication issued
after the date of the enactment of this Act for the Office of
the Law Revision Counsel shows that the laws reflected in
subchapter II of chapter 20 and chapter 22 of nonpositive law
title 21 of the United States Code have been repealed.
SEC. 8. DEFINITIONS.
In this Act, the terms ``agency'', ``appropriate
congressional committees'', ``Director'', ``drug'',
``emerging drug threat,'' ``illicit drug use'', ``illicit
drugs'', ``National Drug Control Program Agencies'', and
``Office'' have the meaning given those terms in section 1001
of title 31, United States Code, as added by section 2(c).
The SPEAKER pro tempore. Pursuant to the rule, the gentleman from
Michigan (Mr. Mitchell) and the gentleman from Maryland (Mr. Cummings)
each will control 20 minutes.
The Chair recognizes the gentleman from Michigan.
general leave
Mr. MITCHELL. Mr. Speaker, I ask unanimous consent that all Members
may have 5 legislative days in which to revise and extend their remarks
and include extraneous material on the bill under consideration.
The SPEAKER pro tempore. Is there objection to the request of the
gentleman from Michigan?
There was no objection.
Mr. MITCHELL. Mr. Speaker, I yield myself such time as I may consume.
Mr. Speaker, I rise today in support of H.R. 5925, introduced by the
gentleman from South Carolina, Chairman Gowdy.
The Coordinated Response through Interagency Strategy and Information
Sharing, or CRISIS, Act is a bill to reauthorize the Office of National
Drug Control. This relatively small office plays an important role in
coordinating the Nation's drug control efforts. The office has become
increasingly important as we look to engage governmentwide initiatives
to combat the opioid epidemic.
Over the past 2 weeks, we have passed many good bills to help combat
the opioid epidemic. Each will move us closer to ending the opioid
crisis.
This bill is a critical piece of the puzzle. It ensures Federal,
State, and local governments work with each other and other
nongovernmental entities to achieve the results we are seeking.
Congress needs to provide the Office of National Drug Control the
authorities it needs to lead the effort to combat the opioid crisis.
The CRISIS Act does just that.
The CRISIS Act updates and reaffirms the office's important role.
That includes strengthening certain authorities to empower the office
in the midst of this devastating epidemic.
The opioid epidemic has impacted nearly every community across the
Nation. One person dies about every 4 hours from an opioid overdose.
One of the most important aspects of this bill is a comprehensive
response plan. It is not enough to simply have a plan. We need action
and follow-through to end the opioid crisis.
The CRISIS Act requires measurable objectives so we know whether the
programs we are funding are working.
Accountability is at the heart of this bill. The CRISIS Act requires
the Office of National Drug Control to develop a national strategy to
be carried out by a wide array of agencies. It then requires the office
to oversee and coordinate implementation of that strategy each year. It
requires the office to measure whether the agencies are meeting the
specific goals of that strategy.
Our colleagues in the House and Senate are advancing a number of
bills to address the opioid epidemic, and new initiatives are being
announced daily. I offered an amendment in committee markup, with the
support of Congressman Raskin, which brings in requirements from the
CODE RED Act, sponsored by the gentleman from Pennsylvania (Mr.
Rothfus).
The CODE RED Act and the amendment require a coordinated tracking
system of the Federal funding to be put toward drug control efforts
throughout the country. This system includes a central repository of
grants related to substance abuse treatment, prevention, and
enforcement, and to identify those which are duplicative.
The government needs to know exactly what it is spending, where it is
going, and if it is working. This is not the time to invest in
ineffective strategies. We need to identify resources that work and
apply Federal resources accordingly.
I would like to thank my fellow committee members for accepting the
amendment, the gentleman from Maryland (Mr. Raskin) for offering it
with me, and, of course, Mr. Rothfus for all the work he has done in
finding an effective approach to tackle the opioid crisis.
There are many bills and proposals that seek to end the opioid
crisis, but it will only be possible with commitment to a coordinated
strategy and a unified approach. This bill, through the reauthorization
of the Office of National Drug Control, will provide the coordination,
strategy, and unified approach we need.
This is an important and timely bill. I urge my colleagues to support
it, and I reserve the balance of my time.
House of Representatives, Committee on Oversight and
Government Reform,
Washington, DC, June 5, 2018.
Hon. Edward Royce,
Chairman, Committee on Foreign Affairs,
House of Representatives, Washington, DC.
Dear Mr. Chairman: On May 23, 2018, the Committee on
Oversight and Government Reform ordered reported H.R. 5925,
the ``Coordinated Response through Interagency Strategy and
Information Sharing Act,'' with an amendment, by voice vote.
The bill was referred primarily to the Committee on Oversight
and Government Reform, with additional referrals to the
Committees on Energy and Commerce, Foreign Affairs, the
Judiciary, Intelligence, and Appropriations.
I ask you allow the Committee on Foreign Affairs to be
discharged from further consideration of the bill so it may
be scheduled for floor consideration by the Majority Leader.
This discharge in no way affects your jurisdiction over the
subject matter of the bill, and it will not serve as
precedent for future referrals. In addition, should a
conference on the bill be necessary, I would support your
request to have the Committee on Foreign Affairs represented
on the conference committee. Finally, I would be pleased to
include this letter and any response in the bill report filed
by the Committee on Oversight and Government Reform, as well
as in the Congressional Record during floor consideration, to
memorialize our understanding.
Thank you for your consideration of my request.
Sincerely,
Trey Gowdy.
____
House of Representatives,
Committee on Foreign Affairs,
Washington, DC, June 5, 2018.
Hon. Trey Gowdy,
Chairman, Committee on Oversight and Government Reform,
Washington, DC.
Dear Chairman Gowdy: Thank you for consulting with the
Committee on Foreign Affairs on H.R. 5925, the Coordinated
Response through Interagency Strategy and Information Sharing
Act, and for accommodating appropriate edits in the amended
text of the bill.
I agree that the Foreign Affairs Committee may be
discharged from further action on this bill, subject to the
understanding that this waiver does not in any way diminish
or alter the jurisdiction of the Foreign Affairs Committee,
or prejudice its jurisdictional prerogatives on this bill or
similar legislation in the future. The Committee also
reserves the right to seek an appropriate number of conferees
to any House-Senate conference involving this bill, and would
appreciate your support for any such request.
[[Page H5322]]
I ask that you place our exchange of letters into the
Congressional Record during floor consideration of the bill.
I appreciate your cooperation, and look forward to continuing
to work with you as this measure moves through the
legislative process.
Sincerely,
Edward R. Royce,
Chairman.
____
House of Representatives, Committee on Oversight and
Government Reform,
Washington, DC, June 8, 2018.
Hon. Devin Nunes,
Chairman, Permanent Select Committee on Intelligence, House
of Representatives, Washington, DC.
Dear Mr. Chairman: On May 23, 2018, the Committee on
Oversight and Government Reform ordered reported H.R. 5925,
the ``Coordinated Response through Interagency Strategy and
Information Sharing Act,'' with an amendment, by voice vote.
The bill was referred primarily to the Committee on Oversight
and Government Reform, with additional referrals to the
Committees on Energy and Commerce, Foreign Affairs, the
Judiciary, Intelligence, and Appropriations.
I ask you allow the Permanent Select Committee on
Intelligence to be discharged from further consideration of
the bill so it may be scheduled for floor consideration by
the Majority Leader. This discharge in no way affects your
jurisdiction over the subject matter of the bill, and it will
not serve as precedent for future referrals. In addition,
should a conference on the bill be necessary, I would support
your request to have the Permanent Select Committee on
Intelligence represented on the conference committee.
Finally, I would be pleased to include this letter and any
response in the bill report filed by the Committee on
Oversight and Government Reform, as well as in the
Congressional Record during floor consideration, to
memorialize our understanding.
Thank you for your consideration of my request.
Sincerely,
Trey Gowdy.
____
House of Representatives, Permanent Select Committee on
Intelligence,
Washington, DC, June 11, 2018.
Hon. Trey Gowdy,
Chairman, Committee on Government and Oversight Reform, House
of Representatives, Washington, DC.
Dear Mr. Chairman: On May 23, 2018, H.R. 5925, the
``Coordinate Response through Interagency Strategy and
Information Sharing Act'' was additionally referred to the
Permanent Select Committee on Intelligence.
In order to expedite the House's consideration of the
measure, and in response to your letter dated June 8, 2018,
the Permanent Select Committee on Intelligence will forgo
consideration of the measure. This courtesy is conditioned on
our mutual understanding and agreement that it will in no way
diminish or alter the jurisdiction of the Permanent Select
Committee on Intelligence with respect to any future
jurisdictional claim over the subject matter contained in the
resolution or any similar measure. I appreciate your support
to the appointment of Members from the Permanent Select
Committee on Intelligence to any House-Senate conference on
this legislation.
I would appreciate you including our exchange of letters in
the Congressional Record during floor consideration of H.R.
5925. Thank you for the cooperative spirit in which you have
worked regarding this and other matters between our
respective committees.
Sincerely,
Devin Nunes,
Chairman.
____
House of Representatives, Committee on Oversight and
Government Reform,
Washington, DC, June 18, 2018.
Hon. Rodney Frelinghuysen,
Chairman, Committee on Appropriations,
House of Representatives, Washington, DC.
Dear Mr. Chairman: On May 23, 2018, the Committee on
Oversight and Government Reform ordered reported H.R. 5925,
the Coordinated Response through Interagency Strategy and
Information Sharing Act, with an amendment, by voice vote.
The bill was referred primarily to the Committee on Oversight
and Government Reform, with additional referrals to the
Committees on Energy and Commerce, Foreign Affairs, the
Judiciary, Intelligence, and Appropriations.
I ask you allow the Committee on Appropriations to be
discharged from further consideration of the bill so it may
be scheduled for floor consideration by the Majority Leader.
This discharge in no way affects your jurisdiction over the
subject matter of the bill, and it will not serve as
precedent for future referrals. In addition, should a
conference on the bill be necessary, I would support your
request to have the Committee on Appropriations represented
on the conference committee. Finally, I would be pleased to
include this letter and any response in the bill report filed
by the Committee on Oversight and Government Reform, as well
as in the Congressional Record during floor consideration, to
memorialize our understanding.
Thank you for your consideration of my request.
Sincerely,
Trey Gowdy.
____
House of Representatives,
Committee on Appropriations,
Washington, DC, June 19, 2018.
Hon. Trey Gowdy,
Chairman, Committee on Oversight and Government Reform, House
of Representatives, Washington, DC.
Dear Mr. Chairman: Thank you for your letter regarding H.R.
5925, the Coordinated Response through Interagency Strategy
and Information Sharing Act. As you know, certain provisions
of the bill fall within the jurisdiction of Committee on
Appropriations.
So that H.R. 5925 may proceed expeditiously to the House
Floor, I agree to discharging the Committee on Appropriations
from further consideration thereof, subject to the
understanding that forgoing formal consideration of the bill
will not prejudice the Committee on Appropriations with
respect to any future jurisdictional claim. The Committee on
Appropriations also reserves the right to seek an appropriate
number of conferees to any House-Senate conference on this or
related legislation.
I request you include our exchange of letters in the bill
report filed by your Committee, as well as in the
Congressional Record during consideration of the bill on the
floor.
Sincerely,
Rodney P. Frelinghuysen.
____
House of Representatives, Committee on Oversight and
Government Reform,
Washington, DC, June 19, 2018.
Hon. Bob Goodlatte,
Chairman, Committee on the Judiciary,
House of Representatives, Washington, DC.
Dear Mr. Chairman: On May 23, 2018, the Committee on
Oversight and Government Reform ordered reported H.R. 5925,
the Coordinated Response through Interagency Strategy and
Information Sharing Act, with an amendment, by voice vote.
The bill was referred primarily to the Committee on Oversight
and Government Reform, with additional referrals to the
Committees on Energy and Commerce, Foreign Affairs, the
Judiciary, Intelligence, and Appropriations.
I ask you allow the Committee on the Judiciary to be
discharged from further consideration of the bill so it may
be scheduled for floor consideration by the Majority Leader.
This discharge in no way affects your jurisdiction over the
subject matter of the bill, and it will not serve as
precedent for future referrals. In addition, should a
conference on the bill be necessary, I would support your
request to have the Committee on the Judiciary represented on
the conference committee. Finally, I would be pleased to
include this letter and any response in the bill report filed
by the Committee on Oversight and Government Reform, as well
as in the Congressional Record during floor consideration, to
memorialize our understanding.
Thank you for your consideration of my request.
Sincerely,
Trey Gowdy.
____
House of Representatives, Committee on Oversight and
Government Reform,
Washington, DC, June 19, 2018.
Hon. Greg Walden,
Chairman, Committee on Energy and Commerce,
House of Representatives, Washington, DC.
Dear Mr. Chairman: On May 23, 2018, the Committee on
Oversight and Government Reform ordered reported H.R. 5925,
the Coordinated Response through Interagency Strategy and
Information Sharing Act, with an amendment, by voice vote.
The bill was referred primarily to the Committee on Oversight
and Government Reform, with additional referrals to the
Committees on Energy and Commerce, Foreign Affairs, the
Judiciary, Intelligence, and Appropriations.
I ask you allow the Committee on Energy and Commerce to be
discharged from further consideration of the bill so it may
be scheduled for floor consideration by the Majority Leader.
This discharge in no way affects your jurisdiction over the
subject matter of the bill, and it will not serve as
precedent for future referrals. In addition, should a
conference on the bill be necessary, I would support your
request to have the Committee on Energy and Commerce
represented on the conference committee. Finally, I would be
pleased to include this letter and any response in the bill
report filed by the Committee on Oversight and Government
Reform, as well as in the Congressional Record during floor
consideration, to memorialize our understanding.
Thank you for your consideration of my request.
Sincerely,
Trey Gowdy.
Mr. CUMMINGS. Mr. Speaker, I yield myself such time as I may consume.
Mr. Speaker, I want to thank Chairman Gowdy for his leadership and
for working together to craft this legislation. I thank Chairman
Meadows and Ranking Member Connolly for helping us reach the
compromises that made this legislation possible.
In 1988, Mr. Speaker, Congress created the Office of National Drug
Control Policy. This is the office that should be coordinating our
Nation's drug control efforts and leading our response to the drug
crisis, which is now,
[[Page H5323]]
by the way, killing 175 people per day. Let me repeat that: killing 175
people per day.
However, ONDCP is failing, just when we need it the most. In fact, an
article published this week described the office this way: ``empty
desks, squabbles, inexperienced staff.''
The failure is glaring. For example, the office is required to
produce a national drug control strategy by February 1 of each year.
Two February 1sts have now come and two have gone since President Trump
took office, but the Trump administration still has not come up with a
solution to this most glaring and painful problem. This is simply
unacceptable.
Life expectancy in this Nation is falling because we are failing to
respond appropriately to this drug crisis. We urgently need to
revitalize and strengthen ONDCP.
H.R. 5925, the CRISIS Act, would make changes we need and would
improve our drug control efforts if it is fully funded and
implemented--fully funded and implemented.
{time} 1215
It would expand the office's authority to direct resources where they
are most needed. It would strengthen data collection and analysis to
help us develop the real-time monitoring we need to understand the
rapidly changing dimensions of the opioid crisis.
The bill incorporates several proposals I have offered to give ONDCP
new authorities to coordinate critical aspects of our response to the
crisis.
I have often said that we must go about the business of being
effective and efficient in what we do. These are examples of things
that will make ONDCP more effective and efficient in addressing this
problem.
For example, for the first time ever, it would create a treatment
coordinator within the office responsible for coordinating efforts to
expand the availability and quality of evidence-based treatment.
It would also require the office to develop and promulgate model
standards for treatment facilities. Right now, too many so-called
treatment facilities are taking advantage of desperate families,
charging them outlandish prices, bilking insurance companies, but
failing to help those in need. As a matter of fact, many people are
going into these places seeking to get treatment and come out worse off
because they are not being properly treated.
Remember what I said: We want to be effective and efficient in what
we do, and we want to make sure that taxpayers' dollars are spent
appropriately.
I believe that if H.R. 5925 is enacted and fully implemented, it will
improve our drug control efforts, and, for that reason, I am supporting
the measure.
However, I want to be real clear about something. Even if this bill
is enacted and fully implemented, the drug crisis we are facing will
likely get worse. That is because this bill does not provide the
resources we need to treat millions of Americans who have the disease
of addiction. According to the President's own commission on opioids,
only 10 percent of individuals who need treatment for substance abuse
disorders are getting it.
No one believes that we can fight cancer, or heart disease, or
Alzheimer's if we don't treat people who have these diseases. The same
is true here.
Imagine someone going into a doctor's office and the doctor says:
Well, you are the 10th person, and you are lucky to get treatment. But
the other nine who came before you won't get any treatment.
We will not stand for that. If we don't treat people who are
addicted, we will not solve the drug crisis.
We may pass this bill today, celebrate the passage, and say we did a
great job. We may work with the Senate to send it to the President. The
President might even sign it. But then, next year's overdose fatality
numbers will come out. They will show that deaths are continuing to
rise. They will show emergency room visits increasing again. They will
show the economic effects of a crisis that is already costing us $500
billion a year continuing to grow.
It doesn't have to be this way. No, it doesn't have to be this way.
We don't have to just nibble at the edges or rearrange the deck chairs
on the Titanic.
I have introduced legislation called the CARE Act with Senator
Elizabeth Warren, modeled directly on the highly successful Ryan White
Act, which Congress passed with bipartisan support in 1990 to address
the AIDS crisis.
The CARE Act would provide $10 billion a year in stable, predictable
Federal funding to States, counties, and other frontline responders.
The CARE Act would provide funds for research to train health
professionals to diagnose and treat addiction. It would also provide
half a billion dollars per year to purchase the lifesaving drug
naloxone at discounted prices and distribute it to first responders,
public health agencies, and the public.
I offered the CARE Act as an amendment to this measure considered
this week. My amendment was paid for by rolling back just a portion of
the tax cuts given by the Republican-controlled Congress to the
Nation's largest corporations, including the drug companies who have
used their tax breaks to buy back billions of dollars' worth of stock
rather than lower drug prices. By the way, there is something wrong
with that picture.
But the Republican leadership did not make my amendment in order. The
House never considered it.
I support H.R. 5925 and our critical efforts to ensure that we have
an office that will effectively and efficiently coordinate our drug
control efforts. However, what our Nation truly needs is for us to show
the political courage to choose to save the lives of our fellow
Americans by adequately funding treatment.
Mr. Speaker, I reserve the balance of my time.
Mr. MITCHELL. Mr. Speaker, I yield myself such time as I may consume.
Mr. Speaker, I appreciate the support of my colleague for this
bipartisan effort to address the opioid crisis in this country. I also
appreciate his emphasis on effectively and efficiently addressing that
crisis.
I will note that in the last appropriation cycle, we increased
funding for opioid treatment by almost $4 billion in this year alone.
There is much work to be done; it is a crisis; and we will work
together to address that crisis.
Mr. Speaker, I yield 5 minutes to the gentleman from North Carolina
(Mr. Meadows), the cosponsor of the bill.
Mr. MEADOWS. Mr. Speaker, I thank the gentleman for his leadership on
this particular initiative in managing this bill.
Mr. Speaker, I rise in support of H.R. 5925, the CRISIS Act, a bill I
cosponsored with Chairman Gowdy; my good friend, the ranking member,
Mr. Cummings; as well as the ranking member of the Government
Operations Subcommittee and good friend, Mr. Connolly.
I want to begin by thanking my colleagues for coming together on this
bipartisan bill. H.R. 5925 reauthorizes the Office of National Drug
Control Policy and gives the office greater responsibility by enhancing
the office's authority to coordinate and oversee the national
drug control program at the national, State, and local levels.
It provides communities with a process for sharing information and
best practices, and implements recommendations from the President's
opioid commission.
It requires an opioid response plan to coordinate with the private
sector the implementation of the commission's recommendations and to
facilitate the development of treatment and abuse-deterrent products.
Finally, this bill designates the United States Postal Service as a
national drug control program agency and requires the office to
coordinate actions to reduce the flow of illicit drugs entering the
country through the mail.
The ongoing opioid epidemic has taken countless lives, touching
literally every community in the country. The national response to this
epidemic involves Federal, State, and local governments. It involves
the treatment community, the medical community, the law enforcement
community, and places of worship.
As we mobilize a national response, we must ensure that every effort
to combat this epidemic works and works well. We have all heard too
many tragic, life-changing, and, far too often, life-ending stories of
opioid addiction.
There is no easy way to end this epidemic. By establishing an
effective national response to this epidemic, this bill will support
the people and the communities struggling with this addiction.
[[Page H5324]]
Mr. Speaker, it is the very lives of our friends, our neighbors, and
our family members that depend on us.
Mr. Speaker, I urge my colleagues to support this bill.
I would also like to go a little bit further, though, because so many
times, when we come together in a bipartisan way, it is Members of
Congress who are up here taking the credit for the hard work of a group
that actually, behind the scenes, are doing the work. I thank all of
the majority staff--Katy Rother, Richard Burkard, Betsy Ferguson, and
Sarah Vance; and to Ranking Member Cummings' staff, for all of their
work and dedication as well. And I also thank Sally Walker from the
Office of Legislative Counsel. Many times, they do the work on the
bills behind the scene and nobody ever sees them or thanks them. So, on
this day, I want to make sure that we acknowledge their effort, that it
doesn't go unnoticed.
Mr. CUMMINGS. Mr. Speaker, I yield myself such time as I may consume.
Mr. Speaker, I want to take a moment, before I yield to my
distinguished colleague, Mr. Connolly, to echo what my good friend just
said about our staffs.
I, too, thank our staffs for all that they have done. So often they
are unseen, unnoticed, and feel, I am sure, unappreciated and
unapplauded. But our staffs worked very, very hard on this, and I, too,
give the ultimate applause to them. I want to thank you for recognizing
them.
Mr. Speaker, I also thank Mr. Meadows for working so hard to bring
all this together.
Mr. Speaker, I yield 6 minutes to the gentleman from Virginia (Mr.
Connolly), the ranking member of the Oversight and Government Reform
Committee, a man who has just been tireless on this issue and so many
others, but who has done such a phenomenal job.
Mr. CONNOLLY. Mr. Speaker, I thank my friend from Michigan (Mr.
Mitchell) and my good friend from North Carolina (Mr. Meadows) for
their leadership. But I particularly want to thank my good friend from
Maryland (Mr. Cummings).
Mr. Cummings is not only a legislative expert, but he is also a moral
voice. He speaks with clarity and eloquence, as he did yesterday, about
innocent children being detained at the southern border as an un-
American activity, something that does not reflect our values. And
today, he is lending that same moral voice to the crisis that afflicts
so many communities in America: the opioid addiction crisis.
Mr. Speaker, I rise today in support of the Coordinated Response
through Interagency Strategy and Information Sharing Act, or the CRISIS
Act, to reauthorize and revamp the Office of National Drug Control
Policy.
The chairman and ranking member of our full committee worked closely
together and with committee members to produce a bipartisan bill that
was reported out of the committee unanimously.
I am proud to be an original cosponsor of the CRISIS Act, which not
only reauthorizes ONDCP, but also strengthens that office so that it
has the resources it needs to coordinate an effective response to the
opioid crisis. And that is something Mr. Cummings stressed. It is not
good enough to do something symbolic. We have to ensure it is
effective. ONDCP's responsibilities are to produce a national drug
control strategy.
{time} 1230
Congress created it in 1988 at the height of the crack cocaine
epidemic to oversee Federal drug control efforts and to advise the
President and the administration on drug control policies and
strategies.
It was designed to oversee the National Drug Control Budget to carry
out the goals and policies of that strategy, and to evaluate the
effectiveness of programs across the Federal Government in implementing
the strategy, and to oversee the High Intensity Drug Trafficking Areas
and Drug Free Communities initiatives.
Congress last authorized the ONDCP in 2006. The authorization expired
in 2010. That is 8 years ago. Since then, we have developed an opioid
crisis the magnitude of which we have never seen in America.
While ONDCP has continued to receive annual appropriations, it is
important that Congress reauthorize this program and reflect the crisis
we are in.
The opioid epidemic that is currently ravaging communities has taken
hundreds of thousands of lives and shows no signs of abating. Every
day, 115 Americans die from an opioid overdose.
The epidemic is destroying families, overwhelming first responders,
straining public health, criminal justice, and child welfare resources.
This epidemic doesn't care where you live or what political party you
belong to. The crisis has touched every community and every corner of
our country.
In my State, the Commonwealth of Virginia, opioid overdose deaths
spiked by 40 percent to 1,133 from 2015 to 2016, and deaths from
synthetic opioids rose from 263 to 692 during that time period.
Northern Virginia, where I represent the good people of Fairfax and
Prince William Counties, Fairfax County, for example, reported an
increase from 67 to 97 opioid-related deaths from 2015 to 2016. And
Prince William County, the other county I represent, increased from 26
to 59 deaths in this time period.
Last month, Dr. Rahul Gupta, Commissioner of the West Virginia Bureau
of Public Health, testified before our committee, and he said that the
crisis will get worse before it gets better. That was not welcome news.
Yet despite the President's pledges and his own Commission on
Combating Drug Addiction and the Opioid Crisis recommendation that he
declare an opioid crisis national emergency, the President, President
Trump, took the lesser step of declaring a public health emergency last
October.
Seventeen months into this administration, ONDCP is still without a
confirmed director and the administration has failed to produce a
National Drug Control Strategy.
Instead, the President, President Trump, proposed cutting ONDCP's
budget by more than 90 percent. Thank goodness Congress, on a
bipartisan basis, did not heed that recommendation.
Just earlier this week, the acting head of the Drug Enforcement
Agency announced he is going to be retiring at the end of the month,
stating that running that agency in an acting capacity for so long had
become increasingly challenging.
As this administration continues to fail to address the opioid
epidemic, it is imperative that we take immediate and decisive action
on a bipartisan basis.
Reauthorizing the Office of National Drug Control Policy with
enhanced authorities will improve the coordination and effectiveness of
Federal Government drug control efforts. It is one of the many steps we
can take to address the opioid epidemic. It won't solve everything, but
it is a very important first step.
I hope the administration will join us in fighting this crisis with
real solutions and not empty rhetoric.
Mr. Speaker, I hope my colleagues will join us in supporting this
important bill.
Mr. MITCHELL. Mr. Speaker, I yield myself such time as I may consume.
Mr. Speaker, I appreciate the support of my colleague from Virginia
(Mr. Connolly) for this bipartisan effort. I certainly hope the
American people have the opportunity to see this effort as we address
this crisis on a bipartisan basis. Far too frequently, they see
conflict and disagreement put forth by media and other sources, but
there is a great deal we work together on, and I think we need to
stress that as we talk to people about this crisis.
Mr. Speaker, in a moment, I will yield to the gentleman from
Pennsylvania (Mr. Rothfus), but first let me give him credit, because
he is the sponsor of legislation on which my amendment was based, H.R.
5980, the CODE RED Act.
The CODE RED Act, like the amendment I offered with Mr. Raskin in
committee, requires a coordinated tracking system of Federal funding
put towards drug control efforts throughout our country. It is a smart
idea, especially given the opioid epidemic in our Nation and the costs
of it, and I strongly supported it.
Mr. Speaker, I yield 5 minutes to the gentleman from Pennsylvania
(Mr. Rothfus).
Mr. ROTHFUS. Mr. Speaker, I thank Mr. Mitchell for yielding.
[[Page H5325]]
Mr. Speaker, I rise in support of H.R. 5925, the Coordinated Response
through Interagency Strategy and Information Sharing Act, or the CRISIS
Act.
This bill reauthorizes the Office of National Drug Control Policy,
which has not been reauthorized in a very long time. It makes needed
overhauls and updates to the office and even streamlines the name of
the office to the Office of National Drug Control, or ONDC.
Mr. Speaker, I commend Chairman Gowdy and Ranking Member Cummings for
working in a bipartisan manner. I also thank Representative Mitchell
and Representative Raskin for working with me to incorporate the first
two recommendations of the President's opioid commission into the
CRISIS Act.
I introduced a separate bill, the Coordinated Overdose and Drug
Epidemic Response to the Emergency Declaration Act, or CODE RED Act,
that authorizes ONDC to address those commission recommendations.
ONDC will now be authorized to implement a coordinated tracking
system of all federally-funded initiatives and grants. This will help
identify barriers and gaps in Federal efforts responding to the opioid
crisis and it identifies places where efforts are being duplicated and
potentially wasted. This legislation improves the grant application
process by standardizing and streamlining it.
The mission here is to deploy Federal resources to localities that
need them quickly and efficiently instead of localities wasting
valuable time and resources filling out various agency applications.
More broadly, the CRISIS Act will foster better government
coordination and strategic planning. ONDC has cross-agency jurisdiction
to coordinate the efforts among different agencies, like HHS and DOJ.
When agencies work together, the force-multiplying effect can make a
huge difference.
We are making progress on the opioid crisis. Bipartisan bills like
the CRISIS Act will help win this fight and help the people engage in
the fight, like the North Hills of Pittsburgh's Tracy Lawless.
Tracy participated in the President's Commission on Combating Drug
Addiction and continues to help find solutions back in Pennsylvania.
Mr. Speaker, I thank her and everyone else who is making a
difference.
Mr. MITCHELL. Mr. Speaker, I want to make the gentleman from Maryland
aware that I have no further speakers and I am prepared to close.
Mr. Speaker, I reserve the balance of my time.
Mr. CUMMINGS. Mr. Speaker, I yield myself such time as I may consume.
Mr. Speaker, in closing, I must point out that my Republican
colleagues say they want to address the opioid crisis, yet they are
standing silent as the Trump administration actively tries to destroy
the Affordable Care Act protections for people with pre-existing
conditions, which, by the way, includes substance use disorders.
If we aren't going to take available steps to expand access to
addiction treatment, at least we should all agree that we shouldn't
roll back protections that prevent insurance companies from
discriminating against people with substance use disorders. Therefore,
we should all be working to protect the Affordable Care Act from the
Trump administration's effort to destroy the essential protections it
provides.
Again, I remind all of us that ONDCP is a very important entity and
it has a job to do, and it must be properly funded.
A lot of people, when they give statistics about opioids and drugs,
Mr. Speaker, they find themselves speaking about the dead. Well, I am
here to tell you that there are pipelines to death, and those are the
people who are addicted now. Those are the ones who are thinking about
it, about to start using those drugs. So we must address not only the
deaths and the statistics, but we must address treatment that is
effective and efficient.
Mr. Speaker, again, I am urging my colleagues to vote for this bill,
but I want it to be clear that we should not dust our hands off and say
it is done.
It is not done. There is so much more to do.
Mr. Speaker, I urge all Members to vote for this legislation, and I
yield back the balance of my time.
Mr. MITCHELL. Mr. Speaker, I yield myself the balance of my time.
Mr. Speaker, I appreciate my colleague's support of the bill. In my
brief time here, a year and a half, it has become abundantly clear to
me that rarely do we get to dust off our hands and say we are done
around here.
It has also become clear to me that the debate of the bill rarely
stays on the topic of the bill or solely on the topic of the bill. You
see, the ACA, the Affordable Care Act, is not the sole approach to
addressing healthcare issues in this country, preexisting conditions,
or the preexisting conditions that are affected by drug abuse.
I believe when we passed the American Health Care Act in this House,
that that addressed preexisting conditions, treatment for substance
abuse, and, using the words of my colleague, did so more effectively
and efficiently than the Affordable Care Act does now.
We clearly disagree on that. I respect that, and will continue to
work on it.
Today, we are dealing with this bill.
Mr. Speaker, I urge my colleagues to support passage of this bill,
because I believe that H.R. 5925 is an important step not only in
reauthorizing the Office of National Drug Control, but also in
providing additional resources to do so.
Mr. Speaker, I urge adoption the bill, and I yield back the balance
of my time.
The SPEAKER pro tempore (Mr. Meadows). The question is on the motion
offered by the gentleman from Michigan (Mr. Mitchell) that the House
suspend the rules and pass the bill, H.R. 5925, as amended.
The question was taken; and (two-thirds being in the affirmative) the
rules were suspended and the bill, as amended, was passed.
A motion to reconsider was laid on the table.
____________________